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Abstract
Cirrhosis is the 12th leading cause of death in the United States. It is well
documented end stage liver disease drives a patient to a catabolic state thus depleting
them of essential nutrients. Malnutrition is often unrecognized and untreated in
outpatients. Though BMI, nutritional intake, anthropometric measurements have been
used in clinical trials, there still remains no standard nutritional assessment.
The purpose of this dissertation was to (1) identify the incidence of malnutrition
in patients with compensated and decompensated liver disease utilizing defined
nutritional parameters (Subjective Global Assessment, anthropometric measurements,
hand grip strength, and laboratory values) and (2) correlate with care (hospital visits,
physician appointments, outcome and quality of life) secondary to viral hepatitis,
metabolic and alcoholic liver disease.
The conceptual framework underlying this study is derived from the literature
based on the domains of liver function, nutrition, and malnutrition. Nutrition includes the
chemical substances in food utilized by the body for growth, maintenance, and repair: the
intake, digestion, and assimilation and utilization of nutrients for tissue maintenance and
energy provision.

There is no gold standard for proper nutritional assessment of patients diagnosed
with liver disease; notably, the traditional assessment tools are invalid with end-stage
liver disease. Ascites, edema, and diuretics cause fluctuations in weight and weight
changes. Cirrhosis of the liver drives a patient to a catabolic state, thus depriving them of
essential nutrients. Simple and easily applied methods are needed to identify the patients
approaching the state of malnutrition.
Study findings presented in three papers provides a major contribution in
discriminating the nutritional parameters of different etiologies o f cirrhosis leading to
malnutrition.
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CHAPTER 1
The Problem and Background
Cirrhosis of the liver is the twelfth leading cause of death in the United States
(Heron, Hoyert, Murphy, Xu, Kochanek, & Teejada-Vera, 2009; & Kochanek, Murphy,
Anderson, & Scott, 2004). The cirrhotic liver is characterized by fibrosis and the normal
architecture is converted to structurally abnormal nodules that lack lobular organization.
It involves the entire liver and is irreversible at its late stages. Cirrhosis is a disease of
contrasts in etiology and symptomatology. The most common etiology has been
alcoholic liver disease and chronic viral hepatitis (Hepatitis C and Hepatitis B).
However, fatty liver disease has increasing in prevalence across the world and is known
to progress to cirrhosis and is becoming one of the leading causes of cirrhosis globally.
Cirrhosis can be asymptomatic or presents with manifestions of hepatic decompensation
as evidenced by variceal bleeding, ascites, hepatic encephalopathy, and hepatorenal
syndrome.
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Nutrition is one of the most important factors that can influence overall mortality
and morbidity. There are a variety o f issues that make it difficult for patients with
cirrhosis of the liver to maintain adequate nutritional intakes. At one end of the
spectrum, there is severe nutritional deficiencies related to chronic alcoholic liver disease
and viral hepatitis which has progressed to cirrhosis. At the other end of the spectrum is
nutritional excess related to nonalcoholic steatosis (NASH) or progressive fatty liver
disease (NAFLD). Both ends of the spectrum require specially designed nutritional
plans.
Severe protein caloric malnutrition (PCM) is common in patients with liver
cirrhosis, particularly alcoholics. It seriously undermines the liver’s capacity for
regeneration and functional restoration. Studies have shown the more severe the
malnutrition, the worse the prognosis. Nutritional supplements on an inpatient basis have
been shown to improve nutritional status, as well as the liver function for these patients.
The prevalence of malnutrition is as high as 80% depending on the cirrhotic population
studied (Campillo, Richardat, Scherman, & Bories, 2003; Matos, Porayko, FranciscoZiller, & DiCecco, 2002).
There is no gold standard for proper nutritional assessment of patients diagnosed
with liver disease. Indeed, liver disease also complicates the nutritional assessment
(McCullough, 2000). Notably, the traditional assessment tools are invalid with end-stage
liver disease. Ascites, edema, and diuretics cause fluctuations in weight and weight
changes. It has been well documented cirrhosis of the liver drives a patient to a catabolic
state, thus depriving them of essential nutrients. Simple and easily applied methods are
needed to identify the patients approaching the state of malnutrition. This study is

designed to provide a major contribution in discriminating the nutritional parameters of
different etiologies of cirrhosis leading to malnutrition.
Background
The liver is the largest metabolic organ in the human body and integrates
carbohydrate, fat, and protein metabolism. The liver stores vitamins and activates others.
It detoxifies and excretes endogenous and exogenous waste products.
The majority of the cells found in the liver are hepatocytes. These hepatocytes
are vital in maintaining homeostasis. The functions of the hepatocytes include the
synthesis of most essential serum protein including albumin, coagulation factors, carrier
proteins, hormonal and growth factors, the regulation of nutrients (glucose, glycogen,
lipids, and cholesterol amino acids), the production of bile and its carriers of bile acids,
lecithin, and phosolipids, and the metabolism and conjugation o f bilirubin, anions,
cations, and drugs. Therefore, cirrhosis, a chronic liver disease characterized by
replacing normal liver tissue with fibrosis, scar tissue and regenerative nodules leading to
the loss of liver function, has major nutritional implications.
Cirrhosis represents the final stage o f many chronic liver diseases. It has been
associated with hyponutrition despite the etiology. Malnutrition is an important
prognostic factor in liver cirrhosis (Campillo,Richardet, & Bories, 2006). There are three
common influences which contribute to hyponutrition in the patient with chronic liver
disease. These are: 1) a decrease of limit of intake; 2) impairment of nutrient digestion
and/or absorption; and 3) the interference of nutrient metabolism. The relevant causes o f
dietary insufficiency are anorexia, nausea, vomiting, food tastes non palatable due to
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protein and salt restriction, early satiety, and reflux disease due to ascites and abnormal
gut motility. Pancreatic insufficiency, cholestasis related to fat soluble vitamins, and
drug related diarrhea from ingestion of lactulose, antibiotics, and diuretics are some o f
the causes of malabsorption. Metabolic disturbances due to infections, hemorrhages,
protein catabolism, impaired glucose homeostasis, proinflammatory cytokines of
interleukins, leptins and TNF alpha, and increased lipolysis and enhanced lipid oxidation
contribute to interference of nutrient metabolism(Lee & Nieman 2007; Stratton, Green, &
Elia, 2008).
Protein malnutrition is documented in nearly every etiology associated with
cirrhosis of the liver(McCullough & Buglanesi, 1997). As liver insufficiency increases,
the prevalence of protein malnutrition increases. Protein needs increase during treatment
of malnutrition but in end-stage liver disease, the tolerance is decreased. Low levels of
vitamins A, zinc, and magnesium have been associated with protein calorie malnutrition.
The literature reflects protein calorie malnutrition as a common finding in patients
hospitalized with chronic liver disease; investigations with individuals in an outpatient
clinic are sparse.
The purpose of this study is to identify the incidence o f malnutrition in patients
with compensated and decompensated liver disease utilizing defined nutritional
parameters (Subjective global assessment, anthropometric measurements, hand grip
strength, and lab values) and correlate to care (hospital visits, ER visits, physician
appointments , outcome, and quality o f life). The degree of malnutrition will be
compared in patients with end stage liver disease secondary to viral hepatitis, metabolic
(NASH), and alcoholic liver disease.
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Nutritional Assessment
The Joint Commission on Accreditation of Health Care Organizations (JACHO)
requires a nutritional screening after hospital admission, but there are no universally
recognized or validated standards. The areas routinely assessed are height, weight,
weight change, dietary prescriptions, appetite, presence of chewing and swallowing, and
major food intolerances. In the outpatient setting, dietary assessment should be done to
determine whether the patient’s diet contributes to an increase health risk or existing
chronic disease related problems.
Nutritional assessment is an integral part of patient assessment as it directly
influences clinical outcomes and mortality rates. Malnutrition increases the risk o f
infections, health care costs, and decrease quality of life, prolongs hospitalizations,
recovery after surgery, and life expectancy (Robinson, Goldstein, & Levine, 1987;
Sherlock & Dooley, 2005).
The assessment of the nutritional status is very inaccurate in patients with chronic
liver disease. The traditional measures used to estimate nutritional status have
limitations. Body weight and body mass index (BMI) are insensitive in cirrhotics
because of salt and water retention causing abdominal ascites. Abnormalities of
lymphocyte and decrease plasma protein resulting from ascites, edema, anasarca, and
malnutrition also contribute to the retaining o f fluid. Malnutrition is an important
prognostic factor which can influence the clinical outcome of patients with end stage
liver disease (Campillo et al., 2006; Kondrup 2006).

In summary, end stage liver disease is a significant, chronic health problem.
There is much known about the nutritional intake during inpatient stays, in contrast less is
known about the nutritional aspects that influence the care on an outpatient basis.
Purpose and Aims
The purpose of this descriptive correlation design study is to examine the
relationship between nutritional assessment parameters and care among a sample of
outpatient of adult patients with End stage liver disease (ESLD). Specifically, the aims of
this study are.
Aim 1:
To identify the incidence of malnutrition in compensated and decompensated liver
disease patients with end stage liver disease utilizing assessment parameters
(SGA, anthropometric measurements, hand grip and laboratory values) among a
sample of adult outpatients with end stage liver disease.
Aim 2
Examine the degree of malnutrition in patients with different etiologies of end
stage liver disease (viral hepatitis, metabolic (NASH), and alcoholic liver
disease).
Aim 3
Describe the relationships between malnutrition, hospital visits, ED visits,
physician appointments, outcome, and quality o f life among a sample of adult
outpatients with end stage liver disease.
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Aim 3’
Describe the relationship of the intensity of care management on education and
support lifestyle changes to improve metabolic parameters in patients with fatty
liver disease.
Conceptual Framework
The conceptual framework underlying this study is derived from the literature
based on the domains of liver function, nutrition, and malnutrition. (Figure 1). Nutrition
influences both the physical and psychological well being in a person. There is a
growing awareness one’s nutritional status may impact the quality of life. Good nutrition
is essential for adequate function and survival, but eating also satisfies other needs i.e.s
eating, satisfaction, socialization, and structure to a day (McKenna and Thorig, 1995).
Nutrition includes the chemical substances in food utilized by the body for growth,
maintenance, and repair. It includes the intake, digestion, and assimilation and utilization
of nutrients for tissue maintenance and the provision o f energy.
Specific dietary components may have an influence on the risk of depression,
cognitive impairment, and cognitive decline (Rogers, 2001). Subclinical deficiencies of
antioxidants ( vitamin C,E, beta carotene, vitamin B 12, B6, and folate) and nutrition
related disorders ( hypercholesterolanemia, hyper triglycerideanemia, hypertension,
diabetes) have been identified as potential nutritional related risk factors (Calvanesi &
Bryan, 2001).
The liver plays a key role in supplying nutrition to the body. It delivers the
elements needed by the different body tissues in simple, utilizable nutrients such as

glucose, amino acids, fatty liver, and vitamins. Though the daily amounts of food
consumed by people vary enormously, the nutrient requirements are relatively constant.
Knowledge of liver physiology is essential to understand the mechanisms at work
in end stage liver disease. The liver provides the body’s homeostasis. It is through the
liver; the blood sugar, cholesterol, and blood urea are maintained. The liver regulates
most of the metabolism on the body.

It is in charge of transforming foreign substances

such as toxins in the intestinal flora and the pollutants brought in with food. It does this
through multiple enzymes, which are controlled by numerous hormones.
The liver requires a greater metabolic potential than any other organ of the body.
It is capable of deriving its own energy through the degradation o f carbohydrates and
lipids through its enzymes. It must also turn amino acids into proteins. It has specific
functions in the digestion of the food we eat. Bile is produced in the liver and is the main
means to eliminating cholesterol, and important for the digestion of fatty food. It
receives a variety of sugars in the diet and converts then into a single circulating sugar,
glucose. The liver transforms endogenous metabolites into soluble compounds easily
excreted by the kidneys. The liver detoxifies substances foreign to the body-each
requiring different mechanisms for this detoxification. The liver purifies the blood of
circulating particles.
Malnutrition implies deviations from normal nutrition in which a deficiency or
excess of energy, protein, and other nutrients cause measureable adverse effects on the
body and function of the tissues (Elia et al., 2000). It has been divided into primary and
secondary malnutrition. Primary malnutrition arises in the absence of disease such as

lack of food due to poverty or social isolation. Secondary malnutrition occurs in a
relationship to a disease. In the absence o f disease, the rate and magnitude of weight loss
affect body function. In the presence of disease, nutritional support affects the function
of tissues and cells.
In the presence of disease, nutritional support appears to produce clinical benefits.
Nutritional support affects the function o f tissues and cells. Recognition of dietary
deficiencies and provision of both nutritional support and dietary education are needed to
support the patient in achieving fluid and electrolyte balance, decrease frequent
hospitalizations, and maintain adequate nutritional stores.
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Figure 1: Conceptual Framework Model
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Significance
Malnutrition is often unrecognized and untreated in outpatients. Due to the
extensive role the liver plays in metabolism and maintenance of homeostasis, liver
disorders predispose the patient to malnutrition. Alarmingly, malnutrition evolves prior
to the clinical signs of hepatic insufficiency.
The goals of nutrition are to replenish malnourished individuals, maintain adequate
muscle and energy reserves, and manage the patient’s symptoms to maximize the quality
of life. To assess the overall potential effects of intervention, it is first necessary to assess
the frequency of malnutrition and its consequences. With the standard parameters of
nutritional assessment often invalid in End Stage Liver disease, it becomes difficult to
identify and assess nutritional states. Although there is strong scientific evidence to
support aggressive treatment o f nutritional deficiencies in cirrhosis, few studies have
assessed changes in nutritional status prospectively over the course of liver disease.
This study will add to the empirical base regarding nutritional assessment
strategies to improve the nursing care for patients treated for liver disease disorders. This
knowledge will facilitate the development of evidence based interventions to improve
patient care outcomes (McCullough, 2000; Sobhonslidsuk et al., 2001; & Stratton et al.,
2008).

Chapter 2
Literature Review
Cirrhosis of the liver is a complex pathophysiological process representing the
final stage of many chronic liver diseases. It results in significant morbidity and eventual
mortality in many patients and has been associated with hyponutrition despite the
etiology. The prevalence o f malnutrition is estimated to be between 65-100% in patients
with cirrhosis (Campillo et al., 2003.) The degree of malnutrition is an important
prognostic factor in liver cirrhosis (Campillo et al., 2006). Accurate longitudinal data on
dietary intake patterns, physical activity, and quality o f life would be helpful to the
understanding of how these factors may impact on health and functional status.
Malnutrition o f the patient with liver disease increases the risk of infections,
health care costs and decrease quality o f life and life expectancy (Dan, Kallman.
Srivastava, Younossai, Kim, & Younossi, 2008). Nutritional assessment of patients with
liver disease is critical as it determines interventions that affect clinical outcomes and
quality of life. Numerous studies have furthered our understanding of the role of
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nutritional status in the hospitalized surgical patient (Figueirdo et al., 2006). However
the type of nutrition assessment used with the surgical patient underestimates the
prevalence and severity of malnutrition with cirrhosis.
The literature reflects protein-energy malnutrition (PEM) as a common finding in
patients hospitalized with chronic liver disease (Campillo et al., 2003; Matos et al., 2002).
However there is a paucity of literature on patients treated in outpatient clinics.
Understanding protein calorie nutrition in outpatients with liver disease is essential
because protein needs and tolerance change for these patients as it does for hospitalized
patients who are treated for malnutrition. In end stage liver disease, the tolerance for
protein is decreased.

Protein calorie malnutrition is also associated with low levels of

vitamins A, zinc, and magnesium.
The causes of malnutrition in liver disease are complex and multifactoral. There are
three common influences which contribute to hyponutrition in the patient with chronic
liver disease. These are: 1) a decrease of limit of intake; 2) impairment of nutrient
digestion and/or absorption; and 3) the interference o f nutrient metabolism. Inadequate
dietary intake is attributed to many factors-loss o f appetite, anorexia, nausea and
vomiting, early satiety, taste abnormalities, reflux disease and impaired expansion of the
stomach capacity ( Aqel, Scolapio, Dickson, Burton, & Bouras, 2005; Plauth & Shutz,
2002; Sobhonslidsuk, Roongpsiuthipong, Nahtir, Kulapongse, Songchitsomboon,
Sumalnop, & Bussagom, 2001).
Inadequate dietary intake is associated with anorexia, nausea, encephalopathy,
and gastritis. Frequently there is restriction of Na and protein due to ascites and edema
decreasing the palatability of the food. Reflux disease is associated with increased ascites
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causing nausea. Impaired digestion and absorption is a contributing factor to
malnutrition. There is a bile salt deficiency, bacterial growth, and altered intestinal
motility associated with the antibiotics, lactulose, diuretics, and cholestrigramine given
the patient to improve liver function and decrease encephalopathy. Portal hypertension
changes the intestine, creates mucosal injury, and increases intestinal permeability.
Cirrhosis represents an altered state of starvation. There is hypermetabolism
during complications of infections, hemorrhage, ascites and decompensation. An overall
protein loss results from a reduced synthesis of urea and hepatic proteins, decrease
intestinal protein absorption, increased urinary nitrogen excretion, and a lowered ratio of
branched-chain to aromatic amino acids. The protein catabolism causes inflammation
and impaired liver synthesis. Impaired glucose homeostasis is a result of hepatic insulin
resistance and altered glucogenesis, low glycogen stores, and impaired glycogenesis.
Classification of Cirrhosis
The Child Pugh score was based on the Child Turcotte classification (Pugh,
Murray Lyon, Dawson, Pietron, & Williams, 1973) and has been widely used as an index
of disease severity e.g. Grade A (mild) to Grade C (severe),for patients with end stage
liver disease.. There are five factors included in the Child Pugh classification, 2 clinical
factors: ascites, hepatic encephalopathy, and 3 laboratory factors: levels of bilirubin,
albumin, and prothrombin time. The grading system indicates the degree of hepatic
reserve and function. The major criticism of this scoring system is the subjectiveness
involved in evaluation ascites and hepatic encephalopathy. This can cause and does
cause differences in patients with very similar laboratory markers. However, it remains
the most common and feasible method to categorize cirrhotic patients.
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major food intolerances. In the outpatient setting, dietary assessment should also be done
to determine whether the patient’s diet contributes to an increase health risk or existing
chronic disease related problems.
Despite liver disease being the primary cause o f malnutrition, it is often
unrecognized and is untreated particularly in outpatients. Further insults to the liver at
this stage, can lead to decompensation, fluid retention (ascites) and encephalopathy.
Clinical detection of malnutrition usually occurs in the advanced stages of deficiencies of
nutrients. Biochemical or other tests can identify the deficiency before the specific
clinical manifestations become apparent. Detection o f subclinical malnutrition has the
obvious advantage that a condition can be identified and treated at an early stage to
improve or prevent progression o f the condition.
Malnutrition is an important prognostic factor which can influence the clinical
outcome of patients with end stage liver disease (Campillo, Richard et al., 2006;
Kondrup, 2006). Anthropedric tools-MAMC, hand grip strength are known to be
predictors of malnutrition in adults with cirrhosis. The use of skin fold anthropometric
measurements have been shown to correlate most reliably with malnutrition in liver
patients but not with the severity of liver disease. Albertino, Gatta, Amobdio, Merkel,
DiPascoli, Bofo, & Caregaro (2001) included mid-arm muscle circumference (MAMC)
and triceps skinfold thickness (TST) metrics and found improved prognostic accuracy of
the Child Pugh score. Abbott, Thomson, Steadman, Gatton, Bothwell, Kerlin, Wall &
Lynch (2001) found advanced Child Pugh scores were associated with diminished muscle
status. Malnutrition occurs in all clinical stages, but it becomes more severe related to
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the degree of liver injury. Malnourished patients have an increased prevalence in
morbidity and mortality (Gunsar et al., 2006).
The assessment of the nutritional status is very inaccurate in patients with chronic
liver disease. The traditional measures used to estimate nutritional status have
limitations. Body weight and body mass index (BMI) are insensitive because of salt and
water retention. Abnormalities of lymphocyte and decrease plasma protein also
contribute to the retaining of fluid. Bioelectrical impedance analysis (BIA) is hampered
by body water retention. Nonetheless, The European Society for Clinical Nutrition and
Metabolism identify the Subjective Global Assessment (SGA) and anthropometric
parameters as reliable in assessing the nutritional state of cirrhotic patients (Figueiredo,
De Mello Perez, & Kondo, 2005)
The required amounts o f essential nutrients differ by age and physiologic state.
Energy intake must match energy output to maintain one’s weight. Restoring energy
expenditure (REE) and physical activity are the major components o f energy output.
Illness alters the ability of the body to engage in physical activity and its REE.
Sodium concentrations have been recognized as an important prognostic factor in
liver cirrhosis. Hepatorenal syndrome, ascites, and death from liver disease are
associated with hyponatremia ( Arroyo &Colmenero 2003; Borroni, Maggi, Sangiovanni,
Cazzaniga, & Salerno, 2000).

Kim, Flamm, Di Bisseglie, and Bodenheimer (2008)

added sodium concentration with the MELD score and found it to be significantly
associated with mortality.

The literature reflects protein calorie nutrition is a common finding in patients
hospitalized with chronic liver disease. However, investigations o f individuals in an
outpatient clinic are rare. Most patients are also non patients with chronic alcohol abuse.
Protein calorie malnutrition is frequently found in patients with end-stage liver disease.
Protein needs increase during treatment o f malnutrition but in end-stage liver disease, the
tolerance is decreased. Low levels o f vitamins A, zinc, and magnesium have been
associated with protein calorie malnutrition.
Fat soluble vitamins (A, D, E, and K) are closely associated with lipids. They can be
stored and their functions are generally related to structural activities.

Vitamin A. There

are two dietary forms of vitamin A-retinol and carotene. Retinol is found only in animal
foods and its compounds are deposited primarily in the liver. Carotene is found both in
animal sources as well as in plants. It is converted to vitamin A in the liver. Vitamin A
and carotene are absorbed through the intestinal mucosa, entering the blood stream via
the lymphatic system and carried to the liver for storage and distribution to the cells.
Vitamin A plays a role in iron utilization, humoral immunity, vision adaptation to light
and dark, t-cell mediated immunity, natural killer cell activity, and phagocytosis.
Vitamin A decreases with cirrhosis and protein energy malnutrition; It increases with
hepatosplenomegaly, hypercholesterolemia, and hyperlipidemia.
Vitamin D. There are two compounds with Vitamin D activity-ergocalciferol and
cholecalciferol. Vitamin D is involved in the regulation of calcium and phosphorus. It
also works with other vitamins- A, C, and K, hormones, and minerals-calcium,
phosphorus, and magnesium to affect bone growth. It is found naturally in fish, liver and
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oils; it is fortified in dairy products. In liver disease, the concurrent use of thiazide and
diuretics can lead to hypercalcemia.
Vitamin E. Vitamin E, also known as tocopherol, is a generic name for a group
of compounds with similar physiological activity. It oxidizes very slowly giving it an
important role as an antioxidant. It neutralizes free cell radicals and provides a protective
role in preventing oxidation of the unsaturated fats. Vitamin E works with a seleniumcontaining enzyme to provide another mechanism of protection for the cell membrane of
fatty acids for the oxidative damage. Vitamin E decreases with malabsorption syndromes
with steatorrhea and in protein energy malnutrition.
Vitamin K. Vitamin K is synthesized by intestinal bacteria and can be found in
plants. It requires bile salts and pancreatic secretions for absorption. As with vitamin A
it is transported via the lymphatic system to the liver for storage. The major function of
vitamin K is to catalyze synthesis of blood clotting factors by the liver. It is essential for
maintaining normal levels of four blood clotting factors-prothrombin (factor II), serum
prothrombin conversion accelerator (Factor IH), plasma thromboplastin component
(factor IX), and Stuart-Prower factor (Factor X). Vitamin K activates each of these
protein synthesized by the liver. Decreases in vitamin K are seen in patients with liver
disease and high phosphates.
Water soluble vitamins cannot be stored, though they are generally distributed
through the body tissue maintaining a tissue saturation level. They are easily absorbed
and transported to the cells and their function is related to cell metabolism and structure.
These are B complex and Vitamin C.

20

Vitamin C. Vitamin C is also an antioxidant along with Vitamins A and E.
Vitamin C is required to build and maintain body tissues-bone matrix, cartilage, dentin,
collagen, and connective tissues. It promotes non-heme iron absorption, carnitine
biosynthesis, and conversion of dopamine to norepinephrine. A decrease in vitamin C is
seen in alcohol abuse, inflammatory disease, and oxidative damage.
Biotin is a micronutrient involved in glucogenesis. It is a coenzyme in
metabolism that functions on the tricarboxyloc cycle for release o f energy. Proteinenergy malnutrition can lead to a deficiency in biotin. Clinical signs of biotin deficiency
include nausea and depression.
Vitamin B12-cobalmin deficiency is associated with deficiencies in vitamin B6
and folate. It is a coenzyme in the synthesis of hemoglobin, RBC’s, and DNA. Folic
acid is used in the synthesis of DNA and helps convert vitamin B 12 to a coenzyme form
in the body. It is needed for growth and development of RBC’s, and helps to lower
homocysteine levels in the body by breaking down amino acids. It goes through the
enterohepatic circulation to be regulated.
Vitamin B6 pyridoxine is a coenzyme in amino acid, lipid, and protein
metabolism, erythrocyte function, modulation o f hormones, nervous system function, and
direct conversion of tryptophan to niacin or to serotonin. Vitamin B2 riboflavin is a
coenzyme in protein and energy metabolism and conversion of other vitamins into active
forms. The thyroid adrenal hormone controls the conversion to the coenzyme forms.
Vitamin B 1, thiamin, is a coenzyme in carbohydrate metabolism. A decrease in
thiamine may elicit Wemicke-Korsakoff syndrome and Beri-Beri cardiomyopathy.

Nutritional Assessment Measures
There have been a variety of comprehensive assessment tools utilized in an attempt to
identify patients at risk of or with malnutrition, yet the literature reflects conflicting
information on the patient with End Stage Liver Disease. There is no gold standard for
proper nutritional assessment of patients diagnosed with liver disease since liver disease
also complicates the nutritional assessment (McCullough, 2000). The traditional
assessment tools are invalid with end-stage liver disease. Ascites, edema, and diuretics
cause fluctuations in weight and weight changes. Bioelectrical impedance and dual x-ray
absorptiometry are altered by fluid retention (Figueiredo et al., 2005; Figueiredo et al.,
2006). The search continues for the ideal nutrition marker. Early identification of the
malnourished cirrhotic patient, regardless of etiology, is essential to develop effective
interventions. The nutritional goals include providing adequate calories, protein, and
nutrients to support hepatocyte regeneration within the existing metabolic alterations of
liver disease.
Malnutrition can lead to further morbidity with increase rates of septic
complications, poorer quality o f life, reduced life span. The liver plays a key role in the
carbohydrate, lipid and nitrogen metabolism within of our bodies. Therefore, cirrhosis
has major nutritional implications. Severe protein caloric malnutrition (PCM) is common
in patients with liver cirrhosis. It seriously undermines the liver’s capacity for
regeneration and functional restoration. Studies have shown the more severe the
malnutrition, the worse the prognosis. Nutritional supplements on an inpatient basis have
been shown to improve nutritional status as well as the liver function for these patients.
Prevalence is as high as 80% depending of the cirrhotic population studied (Campillo et
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al., 2002; Matos et al., 2002). Malnutrition affects lean body mass wasting. Decreases in
vitamins, metals, and plasma protein may occur before lean body mass wasting (Matos et
al., 2002; McCullough & Falck-Ytter, 1999).
Nutrition was used as a prognostic indicator of the Child Turcotte classification for
estimating mortality in patients having portocaval shunt surgery (Child & Turcotte,
1964). It has been shown nutrition in alcohol liver disease, decreased infections,
enhanced wound healing, and decreased the need for hospitalizations (Hirsch, Bunout, de
la Maza, Iturriaga, Petermaim, Icazar, & Gattas, 1993).
European Society for Clinical Nutrition and Metabolism argue simple bedside
methods for SGA and anthropometric parameters are reliable in assessing nutritional state
of cirrhotic patients.
However, the obstacles continue in the evaluation of nutritional status in patients with
cirrhosis. Weight is affected in the presence of ascites and edema. Though the patient
may increase weight, lean body mass might be reduced. Albumin and pre-albumin are
related to low levels of synthesis rather than poor nutritional status, though nutrition does
play a role. Indeed, anthropometric measurements may be unreliable due to third
spacing. This may result in an over-estimation of these values. Additionally, there may
be potential problems associated with poor inter-observer reproducibility.

Hand grip

strength and respiratory muscle strength may be more useful when taken serially. The
SGA has an inter-observer reproducibility rate of 80%. See Table 1 for Studies which
Identified level of malnutrition.
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Table 1: Prevalence of Malnutrition in Patients with Liver Disease
Author

Alberino,
F.; Gatta,
A.;
Amodio,
P;
Merkel,
C.;Di
Pascoli,
L.; Bofo,
G.„ and
Caregaro,
L.

Measured
Defined
malnutritio
n
MAMC
MAMC
TSF
and/or
BMI
TSF < 10
percentile

Inclusion/Excl
usion criteria

results

reference

Hospitalized
with liver
cirrhowsis,
Child A, B, or
C

54%
malnutrition

(2001)
Nutrition and
survival in
patients with
liver
cirrhosis.
Nutrition 17,
445-450

Examined
212 patients
in study
143 male, 69
F
Mean age
57.4 SD 10.4
years
Mean BMI
Child A 26.2
(SD 4.2)
Child B 25.0
(SD 4.3)
Child C 26.0
(SD 4.0)

Kalaitzak
is, E.;
Rolf
Olsson,
R.;
Henffidss
on, P.;
Hugosson
,i.;
Bengtsso
n,; Jalna,
R.;
Bjomsso
n, E.

Anthropometr Liver cirrhosis
Tricep
fold and/or y
of any cause
-tricep skin
mid-arm
muscle
fold thickness Liver cirrhosis
was
circumfere -mid arm
nee below muscle
established
5th
circumference histologically
or based on
percentile
Estimation of presence of at
based on
age and
recent weight least 2 of
sex
following:
change
characteristic
Dry weightimaging
weight after
features,
last
esophageal or
paracentesis
gastric varices,
or before
ascites or
ascites
increased
development. international
Expressed as
normalized

128 patients
agreed to
participate.
Not possible
to calculate
dry weight
loss during
preveious 3
or 6 months
in 11% and
16%
respectively.
62% stable
weight
7% weight
increase
Patients with

(2007)
Malnutrition
and diabetes
are related to
hepatic
encephalopat
hy in patients
with liver
cirrhosis.
Liver
International
1194-1201
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percent of
actual body
weight
Weight-light
clothing
without shoes
BMIcalculated.
Unintentional
weight
change of
more than 1
kg that could
not be
explained by
ascites or
edema during
previous 3-6
months was
noted
Fasting
plasma
glucose
Fasting serum
insulin
Insulin
resistance

ratio (INR) not
attributed to
any other
cause.
Swedish
speaking
Able to give
informed
consent
No patient on
dialysis or
hepatorenal
syndrome.
Pts
hospitalized
because of
acute illness
were allowed
when stable.

or without
malnutrition
do not differ
in proportion
of etiology
of liver
disease or
severity of
liver
cirrhosis (CP
or MELD)
Malnutrition
not found to
be related to
ascites
Muscle mass
was related
to plasma
amnonia
level--? Due
to skeletal
protein
catabolism.
Association
of diabetes
with Hepatic
encephalopat
hy. Previous
association
with
hyperinsulin
emia and
acute
hyperglycem
ia have been
proposed to
have direct
affect on
cognition.
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Figueired
o, F. A.;
Perez, R.
; Kondo,
M.

Overnight
fasting

Diagnosis of
liver cirrhosis
based on
Anthropometr clinical
evidence or
y
liver histology
-height
-weight
-presence of
portal HTN
BMI
and hepatic
calculated
insufficiency
Blood tests
Severity
-albumin
graded by
(g/dL)
child-pugh
Bilirubin
(mg/dL)
scores
Prothrombin
activity (%)
Patients with
Lymphocytes HCC,
malabsorption,
(cells/mm3)
ADDs excluded
Body
Fluid retention
composition
-DEXA to
defined by
derive a
presence of
multicompart peripheral fluid
accumulation
ment model
consisting of
(edema) and
clinincally
BCM, TBF,
detectable
ECW, and
ascites.
total boy
minerals
(TBM)bromide
cocktail used
-comparison
ofbody
composition
measures
between CP
classes was
carried out by
one-way
ANOVA.
Tukey’s test
was used to

17 control
patients; 79
patients with
CP scores
Measuremen
t ofbody
composition
essential to
assessment
of true extent
of
malnutrition
in cirrhosis.
Severity of
altered
altered body
composition
profile was
related to
clinical stage
of liver
disease.
Pronounced
loss o f body
fat initially
followed by
accelerated
loss o f BCM
in advanced
stages of
cirrhosis.
Significant
losses in
body
composition
occur in
patients with
only mild
hepatite
dysfunction
and no

(2000) Effect
of liver
cirrhosis on
body
composition:
evidence o f
significant
depletion
even in mild
disease.
Journal o f
Gastroenterol
ogy and
Hepatology2
0, 209-216
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correct for
multiple
comparisons

Alvaresda-Silva,
M.;
Silveiria,
T. R.

Malnutriti
on was
defined by
a result
below the
mean +/two
standard
deviations
in hand
grip/

Tissue-loss
pattern
calculated
through
percentile
distribution
table by sex.
Reduced if
<50%
SGA
PM
-visceral
proteins
prealbumin
-retinolbinding
protein

Handgrip
strength

obvious
malnutrition.

145 patientscross sectional
assigned to 1
of 3 groups
group 1-50 pts
with cirrhosis;
group 2-46 pts
with HTN;
group 3-49 pts
with functional
gastrointestinal
disorders.

Changes in
ECW
(increase)
and ICW
(decrease)
noted before
fluid
retention was
seen
clinically.
Prevalences
of
malnutrition
were 28% by
SGA; 18.7%
by PNI; 63%
by handgrip.
Handgrip
predicted a
poorer
outcome

InclusionSex did not
histologic
influence
confirmation
nutritional
with cirrhosis
status
or high
according to
suspicion due
SGA or PM
to medical hx,
pe, and
Need
complementary additional
tests.
studies to
demonstrate
Excluded-pts
that
with diabetes
nutritional
mellitus,
replacement
is reflected
acquired
by muscle
imminodeficiency
function as
syndrome,
measured by
tuberculosis,
dynametry
chronic renal
and by

(2005).
Comparison
between
handgrip
strength,
subjective
global
assessment
and
prognostic
nutritional
index in
assessing
malnutrition
and
predicting
clinical
outcome in
cirrhotic
outpatients.
Nutrition, 21,
113-117.
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Campillo
m B.;
Richardet

, J- P.;
Bories, P.
N.

Tai,
M.L.,
Goh, KL„
MohdTaib,
S.H.,
Rampal,
S.,
Mahadev
a, S.

Malnutriti
on defined
as BMI <
22 for no
ascites; <
23 for
mild
ascites,
and <25
for tense
ascites

MAMC
<5%

failure, muscle
disease, and/or
rheumatologic
disease
875 study
BMI
populations
and 294
Mid arm
cirrhotic
muscle
circumference patients
Triceps
skinfold
thickness

Anthropometr

y-

BMI, MAC,
TST,
SGA
indicating
malnutritio handgrip
strength,
n
visceral
proteins,

Inclusion-18
years or older,
admitted to
hospital for
decompensatio
n of cirrhosis
Exclusionpatients with
HCC, grade 3
or 4 HE

clinical
outcome.

BMI is a
reliable
parameter to
detect
malnutrition
with BMI
cutoffs.

Malnutrition
in 50% of
Malaysia
patients
Fat stores
depletion in
30%

lean body
mass,
SGA
Indirect
calorimetry
Physical
activity

Riggio,

0 .,
Angeloni,

s,
Ciufon, L
et al.
Houissa,
F.,
Salem,
M.,
Debbeche
, R.,
Mouelhi,

Validation of
body mass
index for the
diagnosis of
malnutrition
in patients
with liver
cirrhosis.
Gastroenterol
ogy in
Clinical
Biology
30(10), 113743.
(2010)
Anthropomet
ric,
biochemical
and clinical
assessment of
malnutrition
in Malaysian
patients with
advanced
cirrhosis 9,
27-34.

Mid arm
muscle
circumfere
nee
(MAMC)
and/or
Triceps

Anthropometr
ic
measurements
and
biochemical
analysis

44 consecutive
cirrhotic
patients (21
men, 23
women)
hospitalized

High
prevalence
of
malnutrition
associated
with severity
of liver

(2010).Evalu
ation of
nutritional
status in
patients with
liver cirrhosis
La Tunisie
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L.
Bouzaidi,
S., Ben
Rejeb,
M,
Mekki,
H., Said,
Y.,
Trabelsi,

skinfold
thickness
(TST)
below the
5th
percentile
or less
than 60%

Child A=9
Child B=26
Child C=9

cirrhosis
Anthropetric
paraments
valuable
tools for
malnutrition
diagnosis

Medicale, 88,
76-79

Weightage 42 cirrhotic
Height/age children and
Body mass adolescents
index
between 3
months and
Triceps
18 years
skinfold
thickness
Arm
muscle
circumfere
nee

Child A=22
Child B=15
Child C=5

Triceps
skinfold
thickness
best reflected
nutritional
risk

(2007)
Nutritional
risk and
malnutrition
determination
by
anthropometr
y in cirrhotic
children and
adolescents
Arquivos en
Gastroenterol
ogia 44, 3459

s.,
Najjar, T.
Schneider
, A. C,
Pinto,
R B, and
Silveira,
T.R.

Chronic
malnutrition
status
occurrence
greater in
Height/age
index

<10%
nutritional
risk
<3%
malnourishe
d

Chapter 3
Methodology
The purpose of this study was to examine the incidence o f malnutrition in patients
with end stage liver disease utilizing defined nutritional parameters (subjective global
assessment, anthropometric measurements, hand grip strength, and lab values) and
correlate to care (hospital visits, ER visits, physician appointments , outcome, and quality
of life). In this chapter a description of the design, sample, data collection, and analytic
techniques will be presented. The protection of human subjects and study limitations
will also be addressed.
Specific aims:
A i m 1:

To identify the incidence of malnutrition in compensated and decompensated liver
disease patients with end stage liver disease utilizing assessment parameters
(SGA, anthropometric measurements, hand grip and laboratory values) among a
sample of adult outpatients with end stage liver disease.
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Aim 2
Examine the degree o f malnutrition in patients with end stage liver disease
secondary to viral hepatitis, metabolic (NASH), and alcoholic liver disease.
Aim 3
Describe the relationships between hospital visits, ED visits, physician
appointments, outcome, and quality of life among a sample of adult outpatients
with end stage liver disease.
Aim 3’
Describe the relationship of the intensity of care management by the Advanced
Practice Registered Nurse on education and support of lifestyle changes to
improve metabolic parameters in patients with fatty liver disease.
Design
A descriptive, repeated measures, correlational design was used to examine the
relationship between nutritional assessment parameters and care while an outpatient of
adult patients (>18 years) with end stage liver disease (ESLD).
Sample and Sampling
A purposive sample o f 50 outpatients with end stage liver disease, secondary by
histology or clinical picture to viral hepatitis, metabolic (NASH), and alcoholic liver
disease were recruited from a community based hepatology clinic located in Southern
California. There are two locations of this clinic-Coronado and San Clemente. These
clinics provide specialized care to address the needs o f individuals with liver disease in
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an effort to manage their liver condition and improve quality of life and survival. The
advantage of this sampling is the clinic is a regional site for patients with cirrhosis o f the
liver. They have over 200 referrals per year to this clinic. End stage liver disease was
defined as an irreversible condition that occurs with progressive liver damage. It leads to
imminent complete failure of the liver and death.
Inclusion criteria:
Subjects met all of the following inclusion criteria to be eligible for participation in this
study:
1. Willing and able to provide written informed consent.
2. Male or female, age eighteen or greater
3. Confirmation of cirrhosis documented by either
a. Liver biopsy
b. Clinical exam, or
c. Non-invasive alternative to liver biopsy such as fibro-test, fibro-scan, or
acoustic radiation force impulse imaging.
4. Subject has not been treated with any investigative drug or device within 30 days
of the screening visit.
5. A female subject is eligible to enter if she is not pregnant or nursing
6. Subject must be in generally good health as determined by investigator.
Exclusion criteria:
1. History of solid organ transplantation
2. Chronic liver disease of hemochromatosis or Wilson’s disease
3. Current history of clinical hepatic compensation (e.g. jaundice, severe ascites,
encephalopathy or variceal hemorrhage
4. Excessive alcohol ingestion defined as >3 glasses per day (1 glass is equivalent to
beer [284 ml], wine [125 ml] or distilled spirits [25 ml] for females and >4 glasses
for males.
5. Patients with hepatocelllular carcinoma or invasive malignancy
6. Malabsorption short bowel syndrome
7. Parental nutrition within the last 3 months,
8. Patient with a comorbidity o f AIDS
9. Patients on renal dialysis or renal failure
10. Rehabilitating infections i.e. Tuberculosis, chronic fungal infections
11. Rehabilitating chronic conditions i.e.
12. Severe pulmonary disease (02 dependent or FEV <50% predicted value)
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13. History of significant cardiac disease (congestive heart failure, myocardial
infarction within last 2 years)
14. Pregnant or nursing female
Participants were identified by the physician and directed to the advanced nurse
practitioner’s clinic.
Instrumentation
Subjective Global Assessment
The independent variable-malnutrition- was measured using the subjective global
assessment. It is a general nutritional assessment based on current weight, height,
nutritional history, changes on physical examination and existing medical conditions.
The patients were classified as being well nourished or having mild, moderate, or severe
malnutrition. High specificity (96%) has been reported in the detection of malnutrition in
liver patients (Detsky, McLaughlin, & Baker, 1987; Jeejeebhoy, Detsky, & Baker, 1990).
Though originally used to categorize surgical patients, this nutritional classification has
been shown to be a reliable nutritional assessment tool for renal dialysis and liver failure
patients (Hasse, Strong, Gorman, & Liepa, 1993). A single clinician collected this data.
Quality of Life
The Chronic Liver Disease Questionnaire is a disease specific instrument. It is
designed to assess the health related quality of life in patients with chronic liver disease.
It is a multidimensional construct which includes the psychosocial, social, functional
aspects, and physical aspects of chronic liver disease. It was developed by Younossi,
Guyatt, Kiwi, & King (1999) for patients with chronic liver disease of all etiologies and
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stages of cirrhosis. It produces a summary score and correlates with the severity of liver
disease. There is construct validity.
The etiology of the cirrhosis was determined by history and routine tests for
Hepatitis. The diagnosis for cirrhosis was determined by history, clinical or liver biopsy
and laboratory data.
Dual Energy E-Ray Absorptiometry
The DEXA scan is used to measure relative visceral and subcutaneous fat
distribution and bone density. The persons who perform X-Ray Bone Densitometry in
California are required to possess a certificate as a California Diagnostic Radiologic
Technologist, California Radiography Supervisor and Operator permit, or an X-Ray
Technician Limited permit in the X-Ray Bone Densitometry Category.
Laboratory Specimens for Blood Work
The Joint Commission has standards which need to be met for a laboratory to
obtain accreditation. The laboratory is required to meet national health and safety
standards. Trained and certified technicians and laboratory scientists manage, study, and
analyze these blood samples. Regulatory agencies o f the government monitor the
laboratories through proficiency testing programs for routine quality control tests for
equipment and test methods, and validating appropriate handling of the samples
collected.
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Table 2: Outcome Variables
Test
Demographics, Medical
History, Family History,
Medications

Clinical Laboratory
Measures

Outcome measures
Age
Sex
Ethnicity
Alcohol use history
Current frequency
(drinks/day)
Maximum consumption
(yrs)
Tobacco cigarette smoking
history
Current/former smoker
Smoking years
Average cigarettes/day
End Stage Liver Disease
Date of diagnosis
Method of Diagnosis
Symptoms of Liver Disease
Past month
Medical/Family history (1st
degree)
Diabetes (type I or II)
Systemic autoimmune
disease
Cancer
Hypertension
Endocrine disease
Cerebrovascular disease
Hyperlipidemia
Coronary artery disease
Kidney disease
Psychiatric disease
Bariatric surgeiy
Medications use within the
past 6 months (including
vitamins and supplements)
Hematology
Hemoglobin
Hematocrit
White blood cell count
Platelet
Chemistries
Electrolytes
Blood urea nitrogen

Method
Interview and chart review

Blood work drawn at
Laboratory per standard lab
protocol. The lab will
provide certification-yearly
to meet standards for blood
sampling and evaluation of
samples.
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Dietary Intake

Body Composition and
anthropometries

Uric acid
HbAlC
Liver Panel
Bilirubin
Aspartate
aminotransferase (AST)
Alanine aminotransferace
(ALT)
Albumin
Prothrombin time (PT)
Fasting lipid profile
Triglycerides
Total cholesterol
HDL cholesterol
LDL cholesterol
Fasting glucose
Fasting Insulin
Vitamins
B1
B12
Folate
Iron
V itD
A
E
K
Copper
Zinc
B6
Total daily calories
Daily fat calories
Saturated fat calories
Unsaturated fat calories
Daily protein calories
Daily carbohydrate calories
Daily mineral intake
Daily vitamin intake
Height
Weight
BMI
Lean body mass
Fat mass
Bone Mass
Tricep skinfold (TSF)
Mid upper arm
circumference (MUAC)

3 day dietary recall

DEXA
Tape measure
Calipers
Dynamometer
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Physical Activity and Sleep
Patterns

Quality of Life

Hand grip strength
Total time spent walking
(daily)
Total time spent exercising
(daily)
Amount of time spent
sleeping (daily)
Perception of illness and
affect on life

Self report

Quality o f Life .
Questionnaire
Chronic
Liver Chronic Disease
Questionnaire

Protocol:
Patients identified with cirrhosis o f the liver were assessed per standard medical practice
with a review of available medical records, thorough clinical history and physical exam.
1.

All patients were seen by physician or nurse practitioner to determine eligibility
for study. If eligibility met, patients were asked to participate in study. The study
was explained and written consent form all subjects was obtained.

2. On initial visit demographics data was collected or reviewed if the patient was
previously seen in the clinic-age, sex, ethnicity, alcohol use history, tobacco
history, medical/family history o f diabetes, cancer, endocrine disease,
hypertension, CVA, hyperlipidemia, liver disease, coronary artery disease,
bariatric disease, medications used within past 6 months including vitamins and
supplements. IF the patient is a smoker, the number of cigarettes smoked per day
and the length of time was also recorded.
3. All patients were evaluated at 1st visit, with 3 months, 6 months ,and 1 year
follow-up by dietary evaluation, clinical evaluation and physical examination.

a. The dietary evaluation included a 3 day dietary intake recall using Diet
Analysis Plus software version 7.1 to evaluate and analyze nutrient intake
for protein, carbohydrates, fat, vitamin e, vitamin d, zinc, magnesium,
vitamin c, vitamin a, calcium and was compared to the recommended
dietary intake. The patient completed the diet and quantities were
estimated by food diagrams (Nutritional Consulting Enterprises twodimensional food portion visual chart) and models.
i. Sleep pattems-number of hours per night, number of times wake
up, naps-length and number
ii. Current physical activity-mode, frequency, intensity, and duration
b. Patients had anthropometric measurements performed-weight, height,
body mass index (looking for trends), triceps, and mid arm circumference.
Measurement of standing height was done using a stadiometer-wall
mounted, and standing weight using a balanced beam scale. BMI was
calculated using weight (kg)/height (m2). The BMI classification is as
follows: underweight ifBMI<18.5, normal weight if BMI 18.5-24.9,
overweight if BMI is 25.0-29.9 and obese if BMI > 30 (WHO, 1998).
Skin fold. Lange Skin fold Calipers were used to measure the triceps and
biceps, and the mid arm circumference was measured 3 three times with
average used with a tape measure (Paper or plastic better?). Skin fold
measurements of the biceps and triceps were measured in millimeters,
three times, and the average was recorded at each of these sites. The
triceps was measured at the mid-point between the acromiale (lateral edge

of the acromial process) and the radial (approximately the elbow joint, on
the mid-line of the posterior surface of the arm. The arm was relaxed with
the palm of the hand facing forward. The vertical pinch was parallel to the
long axis of the arm. The biceps was measured in the same way as the
triceps, but on the anterior surface of the arm.
Muscle strength will be measured using a dyanometer. This is a hand
held device designed to measure muscle strength in a simple way. The
participant was in a standing position with arms at their sides without
touching their body. The elbow was slightly bent. The test was
administered on the non dominant hand. The participant did squeeze the
dynamometer with as much force as possible, being careful to squeeze it
only once. This was done 3 times with a pause o f 10-20 seconds between
to avoid the affects of muscle fatigue. The results were recorded to the
nearest pound or kilogram.
Subjective Global Assessment was completed by researcher at the time
of the visit.
i. The subjective global assessment(SGA) has been found to be
highly predictive of nutritional assessment(Detsky et al., 1987;
Jeejeebhoy et al., 1990). Though originally used to categorize
surgical patients, this nutritional classification has been shown to
be a reliable nutritional assessment tool for renal dialysis patients
and liver failure patients(Hasseet al, 1993). It is based on four
elements of the patient’s history (weight change, dietary intake,

gastrointestinal symptoms, and functional impairment) and three
elements of the physical examination ( loss o f subcutaneous fat,
muscle wasting, and presence of edema, and ascites). The
information is scored as either A, B, or C which corresponds to
the clinical observer’s subjective opinion o f the patient’s
nutritional status. The clinician examines the form to obtain a
general feel for the patient’s status. The more B and C ratings the
patient has, the more likely the patient is to be malnourished. After
evaluation the patients are categorized into three distinct classes of
nutritional status; well nourished, moderately malnourished, and
severely malnourished.
Blood work was done after a 12 hour fast for measurements of glucose,
insulin, triglyceride, HDL, LDL, total cholesterol, HgbAlC, albumin,
aspartate aminotransferace (AST), alanine aminotransferase ( ALT),
alkaline phosphatase, INR, total serum, direct bilirubin, and leptin.
i. Insulin resistance(IR) was estimated indirectly using the
Homeostasis Model Assessment (HOMA) as described by
Matthews (1985). It is calculated as follows: HOMA = [fasting
insulin (uU/ml) * fasting glucose (mmol)/22.5]. There is no
clearing defining value for IR. Many have used HOMA-IR greater
than or equal to 3 as the cut-off value ( Cortez-Pinto and Camilo
2004; Marchesini, Bugianesi ,Forlani, Cerreli, Lenzi, Manini,

Natale, Vanni, Villanova, Melchionda, &Rizzetto, 2003; Machado
& Cortez-Pinto 2005)
e. Additional tests at initial visit and 6 months include CBC, with
differential including total lymphocytes count, BUN serum creatinine, Creactive protein, ferritin homocysteine, serum and ionized calcium, TSH,
serum zinc, selenium, thiamin, riboflavin, plasma 25-hydroxy vitamin D,
plasma vitamin A and retinol binding protein ration.
Body Composition and Distribution
a. Body composition and distribution was determined using dual energy xray absorptiometry (DEXA). The instrument was calculated by according
the manufacturer’s guidelines daily. Lean body mass and fat mass was
determined from the whole body scan. The percent of fat was calculated.
Body mass index was calculated from height and weight. A waist to hip
fat ration will be determined between the fat tissues in the android (central
) and gynoid (hip and thigh) software defined regions.
Classification clinical staging o f cirrhosis. There are two clinical staging methods
for cirrhosis that are widely used. The first is Child-Turcotte-Pugh (CTP) and the
second is Model for End-Stage Liver Disease (MELD). The CPT method utilizes
three quantitative variable: bilirubin, albumin, and platelets or INR and 2
qualitative variables of encephalopathy and ascites. The score ranges from 5 to
15 and is classified as Class A with a score of less than 7, Class B with a score
between 7 and 9 points, and Class C with a score of 10 to 15 points. (See Table 3
Child-Turcotte-Pugh Scoring System). A patient with a score of less than 7,

41
Child A is considered to have compensated cirrhosis and a score greater than 7
(Child B and C) is considered to be uncompensated.
Table 3. The Child-Pugh Score: Grading System for Cirrhosis
Score
Encephalopathy
Grade
Ascites (grade)

1
None

Bilirubin (mg/dL)

<2

2
1-2

2-3

ModerateSevere
>3

2.8-3.5
4-6

<2.8
>6

Absent Mild

>3.5
Albumin (g/dL)
Prothrombin Time 1-4
(sec)

3
3-4
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Table 4: Timeline for Scheduled Visits and Activities for Each Visit
3 mos

6 mos

1 year

XX

XX

XX

XX

XX

XX

XX

XX

Anthroprometrics

XX

XX

XX

XX

Subjective global
assessment
Hand grasp

XX

XX

XX

XX

XX

XX

XX

XX

Physical exam

XX

XX

XX

XX

Blood workcomplete to
include all
nutritional
parameters
Routine blood
work based on
condition
DEXA

XX

XX

XX

XX

XX

Quality of Life

XX

screening

Baseline/day
1

Informed consent

XX

Demographics

XX

Medical history

XX

Vital signs

XX

Height

XX

Weight

XX

strength

XX

XX

XX

XX
XX

XX

3 day diet

XX

XX

XX

XX

XX

Changes in statushospitalizations,
ED visits

XX

XX

XX

XX

XX

43

Analysis
Descriptive statistics (means and standard deviations) were calculated for all
continuous variables and frequencies and percents were generated for the non-continuous
variables. Chi-Square was used to test for differences among groups in nominal
categorical outcomes. Data was analyzed using the Statistical Package for the Social
Sciences (SPSS) version 20.
Primary analysis used one-way analysis o f variance (ANOVA) with one between
subjects factor (group: Child A, Child B, Child C) examining the differences among
cirrhosis groups in nutritients, total body fat (%fat), and muscle strength. When
appropriate (significant ANOVA F value), post-hoc pairwise contrasts using the Tukey
criteria were examined to determine specifically where group differences occurred.
Human Subjects
Prior to the beginning of the study, Institutional Review Board approval was obtained
from all the institutions involved- University o f San Diego’s Institutional Review Board
and the Southern California Liver Center. All participants signed an informed consent
and given a copy of the form to keep. Participants were told they could leave the study at
any time, and that participation/non-participation did have any effect on their ability to be
seen in the clinic. Benefits of participation would include identification of a decrease or
increase in biomarkers that potentially brought to within normal limits with nutritional
intervention.
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Emerging Health Conditions: Non-alcoholic Fatty Liver Disease
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NAFLD: non-alcoholic fatty liver disease
NASH: non-alcoholic steatohepatitis
NAFL: non-alcoholic fatty liver
Abstract
This article summarizes the clinical features, pathophysiology, natural history and
current treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic
steatohepatitis (NASH). The term nonalcoholic fatty liver disease (NAFLD) describes a
spectrum of liver diseases ranging from hepatic steatosis to steatohepatitis, fibrosis of the
liver and cirrhosis. NAFLD is now recognized as one of the most common liver diseases
worldwide and therefore will often be seen by Advance Practice Registered Nurses
(APRN). Nonalcoholic fatty liver disease is correlated with visceral obesity, insulin
resistance and Type 2 diabetes, metabolic syndrome, and lipid deposition in the
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hepatocytes in the liver parenchyma. The pattern of disease is similar to alcoholic liver
disease in those without a history o f chronic alcohol use. It is estimated that 39 to 95%
of obese adults have NAFLD. The prevalence of hepatic steatosis varies with ethnicity.
Hispanics have the highest prevalence of fatty liver at 45%, Whites with 33% and Blacks
with 24%. Treatment of NAJFLD has been focused on treating the underlying metabolic
risk factors.
If left untreated, 5-10% of those with NAFLD/NASH develop end stage liver
disease, some of them will require transplantation albeit the large majority are not good
candidates for liver transplantation (BMI >37). Given the shortage of available organs, it
is imperative to identify and treat NAFLD/NASH earlier. Advanced Practice Registered
Nurses are seeing obese clients, insulin resistant diabetics clients, and metabolic
syndrome clients in primary care settings. We can identify NAFLD/NASH patients
early, provide education for our clients and begin management o f this progressive
disease. We can also identify earlier those patients who will need referral to a liver
specialty clinic for further aggressive management. Thus with early detection, we may
be able to stop the progression of this liver disease.

Non-alcoholic fatty liver disease (NAFLD) is an alcoholic like liver disease that
occurs in individuals who consume less than 20 grams of alcohol per day. NAFLD can
inflict heavy burdens on health and well-being (Sandler, Everhart, Donowitz,
Adams,Cronin, Goodman, Gemmen, Shah, Advic, & Rubin, 2002). Similar to alcoholinduced liver disease, NAFLD encompasses liver damage, ranging from non-alcoholic
fatty liver (NAFL) at the most clinically benign end of the spectrum to cirrhosis on the
opposite extreme, where most liver-related morbidity and mortality occur. In NAFL, the
liver is steatotic (fat) but generally maintaining its structure and liver function. Non
alcoholic steatohepatitis (NASH) is more severe form than NAFL because there is
increased hepatocyte death(steatohepatitis) in addition to steatosis. The liver injury in
NASH triggers a repair and regeneration response that sometimes leads to progressive
fibrosis and cirrhosis, in which the liver is distorted by regenerating nodules and broad
fibrous bands. Persistent abnormal liver enzymes and imaging modalities, however, have
limited sensitivity for detecting liver steatosis, steatohepatitis and cirrhosis. In addition,
there is no single test that can distinguish NAFLD from other causes o f fatty liver
disease. Currently, NAFLD is a diagnosis of exclusion (Brunt, 2004; McCullough, 2004;
& Neuschwander-Tetri & Caldwell, 2003).
The actual prevalence of NAFLD in the United States is unknown, in part because
a liver biopsy is required for a precise diagnosis. Data from the National Health and
Nutrition Examination Survey (NHANES III) suggest 24% o f American adults may have
NAFLD, while other studies suggest that 30% of the population have NAFLD (Sandler et
al. 2002). In 2006 liver disease ranking increased from 5th to 15th as the leading cause of
death depending on ethnicity (Heron et al, 2009).
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Five percent of end stage liver disease has been identified as cryptogenic
cirrhosis, a term used to classify cirrhosis of unknown origin. This is currently the third
most common indication for liver transplantation (Schreuder, Verwer et al. 2008).
NASH can progress to cirrhosis, hepatocellular carcinoma, and liver failure (Browning,
Szcepaniak et al, 2004; Harrison & Bisceglie, 2003; Machado, Marquea-Vidal et al,
2006, & Nomura, Kashiwagiet al, 1988). NASH is now identified as a primary cause of
15 to 73% of cryptogenic cirrhosis. The steatosis characteristic o f NASH disappears with
disease progression, however, making it difficult to identify NASH as the culprit.
NAFLD is emerging as the most common cause of liver disease and it is the probable
cause when patients present with type 2 diabetes, hyperlipidemia, and obesity after
excluding other common causes of chronic liver diseases. Other underlying etiologies
are silent autoimmune hepatitis, unidentified viral hepatitis, occult alcohol abuse or other
toxins, and cholestasis (Ayata, Gordon et al, 2002; Hubscher, 2009, Maheshwari &
Thuluvath, 2006).
Studies have shown a generally low risk o f progression but more rapid
progression is associated with obesity and diabetes. The risk o f progression from
NAFLD to cirrhosis is 1-2% over 15 to 20 years, whereas the risk for progression from
NASH to cirrhosis is 12-20% over 8 years (Adams, Lymp et al., 2005; Adams, Sanderson
et al., 2005; Dam-Lasent, Becker t al.,2009; & Sanyal, Banas et al.,2006).
Limited data suggest that 3% of individuals with NAFLD may have
nonalcoholic steatohepatitis (NASH), with rates rising to 37% among the morbidly obese.
The progression o f cirrhosis to end-stage liver disease is 39-63% in patients with NASH.
O f these patients, 22-33% will experience liver disease-related mortality, with a survival
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time of 5-7 years. The development of ascites is the most common liver-related
morbidity. The mortality rate is higher than in the general population (standard mortality
ratio, 1.34; 95% CI:!.00-1>76;p = 0.03)(Adams, Lymp et al. 2005).
Globally, it Is estimated the prevalence of fatty liver has increased from 14% in
1988 to 31% in 2005 (Adams, Sanderson et al. 2005). For APRNs, this means
approximately 33% of patients have fatty livers. Numerous considerations, however,
may complicate the diagnosis. The differential diagnose one must consider are Wilson’s
disease, autoimmune hepatitis, hepatitis C virus, galactosemia, and alcohol use/abuse.
Additionally, high serum ferritin and transferrin levels need to be evaluated.
The presence of steatosis on histological examination of a liver biopsy is
necessary for a diagnosis of NASH. The steatosis is most commonly macrovesicular,
although some microvesicular steatosis may be seen. In addition, a mixed inflammatory
infiltrate consisting of neutrophils and degeneration and hepatocyte necrosis may be
present. Mallory’s hyaline bodies may also be seen (Harrison & Bisceglie, 2003). (See
table 5.)
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Table 5: Histologic Spectrum of Non-Alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease (NAFLD)
Histologic Spectrum of Liver Disease
type 1-fatty liver (steatosis)

NAFL

Type 2-steatosis + nonspecific inflammation
Type 3-steatosis + ballooning degeneration and

NASH

increased hepatocyte death (steatohepatitis)
Type 4-steatosis + fibrosis and/or Mallory bodies
Cirrhosis

-complication of Types 3 and 4.
Regenerative nodules + fibrosis

Multiple risk factors are associated with non-alcoholic fatty liver disease: obesity
(high BMI or waist to hip ratio), metabolic syndrome, type 2 diabetes mellitus, alcohol
ingestion, female gender and inflammation (including grade and C-peptide). Although
most of the studies have been small and they used a variety of histological scoring
systems, these are the risk factors identified in the studies (Stengel & Harrison, 2006).
It is questionable whether fatty liver is a risk factor for some of these risk factors
or part of a disease complex. Cirrhosis has been found in patients worked up for a
gastric bypass and in patients with cardiac failure not doing well, especially with a
history of diabetes mellitus. NASH has also been identified in patients with a family
history (Rubenstein, Lavine et al, 2008; Younossi, Gramlich et al., 2004).
Obesity related liver disease
Several factors have led to a state o f decreased calorie utilization over the past 50
years. Sedentary lifestyle, energy-dense foods, and increased consumption of foods and
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drinks with high fructose have contributed to an increase in adipogensis. However, while
obesity-related chronic inflammation plays a very strong supporting role in the
pathogenesis of NAFL and NASH, the mechanisms that drive the progression from
NAFL/NASH to cirrhosis remains less well understood.
It is thought to be a two hit process. The first hit is an accumulation of fat in the
hepatocytes. Twenty percent of the glucose eaten at a meal is metabolized by the liver,
but 100% percent of fructose eaten is metabolized by the liver. With an accumulation of
fat in the hepatocytes, there is an increased delivery o f fatty acids to the liver, inhibition
of B-oxidation of fatty acids, decreased synthesis or secretion of very low density lipids,
hyperlipidemia, diabetes mellitus, and obesity. Fat accumulation in NASH is associated
with a decrease in insulin and an increase of fat in the diet. Therefore, a decrease in
glucose uptake and an increase in free fatty acids are seen.
The second hit is thought to be due to an increase in hepatic oxidative stress,
which is greater than the antioxidant defenses. This leads to activation of stellate cells,
causing fibrosis and the generation of proinflammatory cytokines. Inflammation,
hepatocyte swelling, and ultimately death are a result of the proinflammatory cytokines.
This perpetuates the formation of Mallory bodies and fibrosis.
As body mass index (BMI) increases, the fat in the liver increases. Over the past
several decades, Americans have become more overweight. Notably in 2008, there was
not a state within the country with less than 15% obesity (see Figure 2). A key
consequence of obesity is the development of insulin resistance and the metabolic
syndrome. This development provides a critical link between obesity and NAFLD.
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Figure 2: Obesity Trends Among U. S. Adults
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The prevalence of NAFLD and NASH increases among the morbidly obese.
Normal transaminase levels do not exclude NASH or fibrosis (Mofrad, Contos et al.
2003). Patients undergoing bariatric surgery have a prevalence o f 84-96%
NAFLD/NASH, 25-55% progress to NASH. Further breaking down the NASH
components , 34%-47% have fibrosis and 2% to 12% have bridging fibrosis or cirrhosis
(Clark 2006).
Machado (2006) reanalyzed 12 observational and transversal studies involving
1620 patients who had undergone bariatric surgery. All these 12 studies enrolled patients
consecutively and analyzed data prospectively. The prevalence o f steatosis averaged
91% (range 85% to 98%), and the prevalence of NASH averaged 37% (range 24% to
98%). The conditions most frequently associated with NASH were diabetes and insulin

56
resistance. Hypertension was most frequently associated with advanced hepatitic
fibrosis(Machado, Marques-Vidal et al. 2006). Post-surgery, there appeared to be a
decrease in the grade of steatosis and in most cases a decrease in the grade of hepatic
inflammation and stage of fibrosis (Barker, Palekar et al. 2006; de Almeida, Rocha et al.
2006).
Steatosis
Numerous studies have found an increase in alanine aminotransferase (ALT),
triglycerides, and body mass index (BMI) were the most sensitive markers of steatosis.
In the Dallas Heart Study (Browning, 2006), hepatic triglycerides content was
determined by proton magnetic resonance spectroscopy (MRS) in a multiethnic cohort of
2287 subjects. The median hepatic triglycerides content was 3.6% but it varied widely
from 0% to 41.7% (Browning, Szczepaniak et al. 2004). Overall, nearly a third of the
study population had hepatic steatosis, but the prevalence varied by ethnicity: among
Hispanics the prevalence was 45%, among Caucasians 33%, and among Blacks 24%
(Browning, Szczepaniak et al. 2004; Weston, Leyden et al. 2005). The higher prevalence
of hepatic steatosis in the Hispanic population was related to the higher prevalence of
insulin resistance and obesity. However, the lower prevalence of hepatic steatosis in
Blacks was not explained by ethnic differences in BMI, insulin resistance, alcohol
consumption, or medication use(Browning, Szczepaniak et al. 2004). The National
Institutes of Health (NIH) are currently investigating genetic risk factors for NAFLD and
this provides evidence of a genetic component to NAFLD.
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Metabolic Syndrome
The American Heart Association and the National Heart, Lung, and Blood
Institute Scientific Statement (Alberti, et al, 2009; Grundy, 2005) have identified the
metabolic syndrome as a group of interrelated metabolic risk factors. The presence of
these factors identifies a person at risk for atherosclerotic cardiovascular disease and type
2 diabetes mellitus. Key risk factors include abdominal obesity and insulin resistance.
Additionally three of five o f the following risk factors constitutes a diagnosis of
metabolic syndrome: abdominal obesity (waist circumference of >102 centimeters in men
and >88 centimeters in women), elevated fasting glucose of > 100 mg/dL, elevated
triglycerides of >150 mg/dL, low HDL of <40 mg/dL in men and <50 mg/dL in women,
and hypertension, defined as a systolic pressure o f >130 mm Hg and a diastolic pressure
of >85 mm Hg. Metabolic syndrome is associated with a variety of conditions, including
fatty liver (Grundy, Cleeman et al. 2005).
Using the criteria o f the National Cholesterol Education Program’s Adult
treatment Panel HI guidelines, Marchesini and others (2003) found the prevalence of
metabolic syndrome to be 36% in 304 consecutive non-alcoholic fatty liver disease
patients without overt diabetes. The prevalence o f metabolic syndrome increased with
increasing BMI, from 18% in normal weight individuals to 29% in overweight
individuals to 67% in obese individuals. Metabolic syndrome was also significantly
associated with female gender (OR =3.02; 95% Cl: 1.57 to 6.02) and age (OR = 1.54;
95% Cl 1.23 to 1.93 for every 10 years). Eighty eight percent o f the subjects diagnosed
with NASH by liver biopsy (120 subjects out o f 163 subjects obtaining liver biopsies)
had metabolic syndrome. The other 43 patients had pure fatty liver disease. Clearly the
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presence of metabolic syndrome places patients at risk of NASH and further progression
to fibrosis and cirrhosis.
Dietary and Lifestyle Habits
Dietary habits may contribute to the development of NASH. When food intake
was reviewed in a cohort of 25 NASH patients and a healthy control matched group for
BMI, age, and gender, the NASH patients were found to consume a diet higher in
saturated fat and cholesterol and lower in polyunsaturated fat, fiber, and antioxidant
vitamins C and E (Capristo, Meiele et al. 2005). In another study, NASH patients were
found to consume a diet higher in total calories (energy) than healthy controls (Musso,
Gambino et al. 2003). Musso (2003) also examined the relationship of dietary habits to
insulin sensitivity and postprandial triglyceride metabolism. They found the insulin
sensitivity index was significantly lower in NASH patients and was correlated with
saturated fat intake and postprandial rise of triglycerides. There was also a suggestion of
a defect in ApoB secretion since the apolopoprotein (Apo) B48 and APO B100 responses
were flat and dissociated from the triglyceride response in NASH patients. Musso and
colleagues concluded dietary habits may promote steatohepatitis directly by modulating
hepatitis triglyceride accumulation and antioxidant activity, or indirectly, by affecting
insulin sensitivity and postprandial triglyceride metabolism.
Much work has been done on the association of dietary intake and metabolic
syndrome, but few studies have focused on dietary habits associated with NAFLD
.Tendler et al. (2007) found in a study o f five patients a low carbohydrate, ketogenic diet
led to significant improvements in liver histology in patients with NASH/NAFLD. There
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were improvements in both steatosis and necroinflammatory grade and there was also
reduction in the fibrosis pattern in three patients. One patient experienced histological
worsening. However, this patient was not compliant with the diet, nor did he lose weight.
It was difficult to determine whether histologic changes were due to a low carbohydrate
diet to the weight loss experienced by participants. This study suggests decreased
carbohydrate intake may have an independent beneficial effect on fatty liver.
Zelber-Sagi et al. (2007) examined the dietary habits o f 349 Israeli volunteers,
findings indicated the NAFLD group (diagnosed by ultrasound)consumed less fish rich in
omega-3, almost twice the amount of soft drinks and27% more meat. The higher intake
of soft drinks and meat was associated with an increased risk o f NAFLD, independent of
age, gender, BMI and total calories. Studies have also shown that a fructose-enriched
diet leads to development of macrovesicular and microvesicular fat deposits and
increases in hepatitis triglyceride and cholesterol levels. These findings suggest high
carbohydrate diets may contribute to NAFLD ((Ackerman, Oron-Herman et al. 2005).
Medications for NAFLD
There is no definitive pharmacotherapy for the treatment of NAFLD. This is a
multifactoral disease in which insulin and insulin resistance plays a fundamental role. Fat
accumulation in the liver is a consequence of lipids in the liver, adipose tissue, muscle
and gut. Anti-oxidants in the hepatocytes are lacking, but this is thought to be due to
increasing oxidative stress. Together these problems cause inflammation and fibrosis
reducing the activation of Kupffer and stellate cells.
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Ongoing studies are looking at pharmacology interventions to prevent disease
progressions. The drugs currently being used are insulin sensitizers (metformin,
pioglitazone, and posiglitazone), antioxidants (vitamins E, C and silymarin),
hepatoprotective agents (betaie, s-adenosyl, and ursodeoxycholic), hypolipidemic drugs
(fibrates, statins, and omega 3 fatty acid), anti-tumor necrosis factor regimens
(pentoxifylline and adiponectin) and angiotensin receptor blockers (losartan)
(Belfort, Harrison et al, 2006; Harrison, Torgerson et al, 2002; Neuschwander-Tetri,
Brunt et al., 2003; Promrat, Lutchman et al., 2004; Schwimmer, Middleton et al., 2005).
The thiazolidinediones class improves insulin sensitivity primarily in adipose
tissue by activating the nuclear transcription factor-perioxisome proliferator-activated
receptor-y (PPAR-Y) through binding ligands. Treatment with pioglitazone along with
changes in diet has found to significantly improve hepatic insulin sensitivity and glucose
clearance. Hepatic fat content declined by 54% after treatment for 6 months with
pioglitazone and diet while it remained unchanged in a group treated with placebo and
diet. Pioglitazone appears to have direct anti-fibrotic effects on the liver by preventing
the activiation of hepatitic stellate cells, resulting in reduced expression of type 1
procollagen, smooth muscle actic and transforming growth factor-Bl (TFG-B1) (Belfort,
Harrison et al. 2006).
Metformin has not shown consistent results in the trials. It improves insulin
sensitivity primarily in the liver, but histologic improvement has been generally limited
(Bugianesi,Gentilcore et al., 2005; Goodarzi & Bryer-Ash, 2005; Loomba, Luchmann et
al., 2006; Nair, Diehl et al., 2004).
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Combining vitamin E with pioglitazone significantly improved metabolic
parameters and reduced steatosis, cytologic ballooning, Mallory’s hyaline bodies and
pericellular fibrosis from baseline(Sanyal, Mofrad et al. 2004). These findings are
promising, however they must be interested with caution due to the limited sample size.
Evaluation of the Individual for the Presence of NAFLD
A thorough history o f the individual and a physical examination begin the process
of identifying NAFLD. NAFLD is the most common cause of asymptomatic elevated
liver enzymes, found in 77% of patients (Cortez-Pinto & Camillo, 2004). The most
frequent symptoms expressed by the individual are right upper quadrant pain, fatigue, and
abdominal discomfort. The examiner may find hepatomegaly and abnormal liver tests.
A complete hepatic panel with gamma-glutamyl transferase, AST, ALT, and total
bilirubin is needed. However, the NIH criteria differ from the laboratory values found on
lab tests. Normal liver enzymes for a woman are ALT of 19 and for a male, 30. Results
higher than these are considered elevated (Prati, Taioli et al. 2002). In NAFLD, ALT is
greater than AST ((Huber 2004).
Additional laboratory tests are needed to exclude alternate causes of abnormal
liver enzymes. A hepatitis panel to rule out viral hepatitis, and iron studies and ferritin
to rule out hereditary diseases such as hemochromatosis are needed. A thyroid panel,
especially thyroid stimulating hormone (TSH), needs to be checked since thyroid
abnormalities may alter liver function.

Anti-liver-kidney microsomal antibodies,

antinuclear antibodies, and anti-smooth muscle antibodies will indicate whether
autoimmune hepatitis is a culprit. Primary biliary cirrhosis is identified by a greater than
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1:4 positive antimitochondrial autoantibody titer. Alpha-1 antitrypsin antibodies help
identify hereditary enzyme deficiency that leads to both lung and liver disease.
There are also noninvasive studies to identify the presence of steatosis.
Sonography is the most commonly used method. Computerized tomography and MRI
have also been used, though none of these are ideal. No imaging study to date has been
able to distinguish between simple fatty liver and NASH or with fibrous NASH.
However, this area continues to be investigated for the ability to assist in the diagnosis of
NASH.
Liver biopsy remains the “gold standard” for the definitive diagnosis of NAFLD.
It completes the work-up in individuals without significant coagulopathy and who are at
high risk for having bridging fibrosis based on other clinical and laboratory parameters.
The decision to perform a biopsy continues to be debated, though a biopsy makes it
possible to predict a patient’s clinical pathway based on the findings of the biopsy.
Simple steatosis has a low likelihood of progression to advanced liver disease. NASH is
more likely to progress to advanced disease, with or without fibrosis. The biopsy,
however, has potential risks related to the procedure itself and the current lack of
treatment for NAFLD.
NAFLD: Therapeutic Approach
Based on the data, it is possible to construct a therapeutic algorithm that can be
used to treat patients with NAFLD. Treatment of NAFLD has focused on the underlying
metabolic risk factors. Those with overt features of metabolic syndrome (obesity,
diabetes, hypertension and dyslipidemia) should have those diseases treated according to
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standard approaches. Regardless of whether or not patients exhibit other features of
metabolic syndrome, all individuals with NAFLD should have some form of therapy for
their liver disease. Fatty liver may be categorized as primary or secondary depending on
the pathogenesis. Distinction between primary and secondary types is important since
these have different treatment and prognosis.
Treatment is guided by the severity of the liver damage, and the degree of proof
of therapeutic efficacy and safety. Patients with simple steatosis should be encouraged to
reduce caloric consumption and increase physical activity, using an approach that
improves insulin sensitivity in diabetes ( Andersen, Gluud et al. 1991; Drenick, Simmons
et al. 1970; Rozenthal, Brava et al. 1967). Patients with steatohepatitis should be given
similar advice and may also be encouraged to enroll in one of the several treatment trials
underway. Patients with cirrhosis should receive standard therapy for portal hypertension
and undergo routine screening for hepatocellular carcinoma. I f hepatic decompensation
ensues, patients without contraindications for surgery should be considered for orthotopic
liver transplant (OLT).
Once NAFLD has been diagnosed, periodic monitoring to assess disease
progression is needed. NAFLD can reoccur after liver transplant, and aggressive efforts
are needed to prevent and treat metabolic syndrome post-OLT(Sutedja, Gow et al. 2004;
Ghali and Lindor.2004). If diet contributes to NASH, then weight loss may help reduce
fat deposits. In women with gestational diabetes, a weight loss of 8% was associated
with significant reduction in liver fat content (39+ or - 5%)(Tiikkainen, Bergholm et al.
2003).
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Summary
Dietary treatment to prevent and control NAFLD has not been clearly defined.
The diet for weight loss remains debatable, though a diet enriched with unsaturated fatty
acids is theoretically reasonable. Restricting calories is known to achieve weight loss.
Foods with a low glycemic index may reduce mean incremental blood glucose. In
summary, lifestyle modifications incorporating a gradual weight loss and increased
exercise are an important component of patient management and are associated with
improved liver histology.
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Facilitating Lifestyle Changes to Manage Progressive Fatty Liver Disease
Abstract:
Background: With the increase in obesity in the United States, and the rising incidence
of metabolic syndrome, more patients are presenting with abnormal liver injury tests
related to fatty liver. There is no standard therapy for fatty liver disease other than
lifestyle changes to combat the metabolic derangement and avoid the progression to
NASH/cirrhosis. The aim of this study was to describe the relationship of the intensity in
care management by the nurse practitioner on education and support of lifestyle changes
to improve metabolic parameters in patients with fatty liver. Methods: Seventeen
patients were identified with a diagnosis of Fatty Liver disease-13 adult patients and 4
pediatric patients. Patients were identified through elevated liver enzymes, and exclusion
of all other possible liver diseases. Patients were followed every 2-3 months initially and
then tailored to the individual patient needs resulting in 1 month to 3 month follow up.
Each structured clinic visit lasted 30-45 minutes to assess patients and discuss lifestyle
changes. Results: Thirteen adults-8 females (62%) and 5 males (38%), age range 29-72
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years and four pediatric subjects-3 males and 1 female, age range 12-17 years were in the
study. The adult participants had an initial BMI of 30.93±3.7, AST 49.5±27.8, and ALT
71.5±43.8, while the pediatric participants had a BMI of 33.33±6.3, AST of 42.3±14, and
ALT 66.65±36.6. During the follow-up period, the adult participants self-selected to
increase frequency of visits to monthly or every other month for self-accountability. Diet
changes were more difficult in adults since 85% of the adult’s skipped either breakfast or
lunch. The adult averaged 4 medications-including antihypertensives, and cholesterol
medications. The pediatric participants continued with every 3 months but increased
their physical exercise to 5 times a week-1-1/2 hours per session. Their diets included
more fruits and vegetables previously lacking. By self-report, they made better choices
through the school lunch program. The BMI remained relatively stable for 6 months for
both groups, though at three months ALT and AST was normal in the adult group in 55%
and 44% respectively. In contrast, 100% of the pediatric participants achieved normal
AST and ALT levels by 3 months. Adolescent growth in height facilitated the mild
changes in the BMI, whereas in the adult, the BMI changes were based on actual weight
loss. Conclusions: Outside clinical trials; (1) management of fatty liver is feasible; (2)
improvement occurs with dedicated time and a contract with the patient-listening to their
individual needs, (3) albeit chemical and metabolic improvement occurs, it is slow, and
(4) pediatric patients require full participation and family support in lifestyle changes of
the patient to achieve the goals of therapy. The trial showed to be labor intensive and this
model could be the most cost effective.

Introduction
Non-alcoholic fatty liver disease is emerging as an increasingly important cause
of liver disease. It is associated with obesity, diabetes, and insulin resistance. Non
alcoholic fatty liver disease (NAFLD) can lead to cirrhosis and may result in significant
morbidity and eventual mortality. Though there is no specific therapy, exercise and
nutritional intervention appears to improve and prevent these inter-related conditions.
The risk of progression from NAFLD to cirrhosis is 1-2% over 15 to 20 years,
whereas the risk for progression from NASH to cirrhosis is 12-20% over 8 years (Adams,
Lymp et al. 2005; Adams, Sanderson et al. 2005; Sanyal, Banas et al. 2006; Dam-Larsen,
Becker et al. 2009). Additionally, there is a more rapid progression of fatty liver disease
when obesity and diabetes confound the health issues.
The changes to the CDC-Behavioral Risk factor surveillance system, which
provides the prevalence of self-reported obesity among United States adults have resulted
in a new baseline. Traditionally the telephone survey was based on land lines, and this
year cell phone users were surveyed to obtain data that better represents the diverse
population (CDC, 2011). This expanded and improved way to gather and process
information does not accurately compare to previous findings. More than one-third of
United States Adults are obese. In fact there is not a state less than 20% obesity. The
Southern States have the highest obesity rate at 29.5% (Table 6). Our clinic population in
Southern California is primarily Hispanic/Latino and the obesity rate is around 40%.
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Table 6: Prevalence of Self-Reported Obesity Among U.S. Adults, 2011

Obesity Prevalence
P rev alen ce o f S elf-R eported O besity A m ong U.S. A dults
BRFSS, 2011

Numerous studies have found that an increase in alanine aminotransferase (ALT),
triglycerides, and body mass index (BMI) were the most sensitive markers of steatosis.
In the Dallas Heart Study, hepatic triglycerides content was determined by proton
magnetic resonance spectroscopy (MRS) in a multiethnic cohort of 2287 subjects. The
median hepatic triglycerides content was 3.6% but it varied widely from 0 to 41.7
percent. Overall, nearly a third of the study population had hepatic steatosis, but the
prevalence varied by ethnicity: among Hispanics/Latinos the prevalence was 45%,
among Caucasians 33%, and among blacks 24% (Browning, Szczepaniak et al. 2004;
Weston, Leyden et al. 2005). The higher prevalence of hepatic steatosis in the
Hispanic/Latino population was related to the higher prevalence of insulin resistance and
obesity. However, the lower prevalence o f hepatic steatosis in Blacks was not explained
by ethnic differences in BMI, insulin resistance, alcohol consumption, or medication use
(Browning, Szczepaniak et al. 2004). The National Institutes o f Health (NIH) are
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currently looking into genetic risk factors for NAFLD which may provide evidence of a
genetic component to NAFLD.
Metabolic Syndrome
The American Heart Association and the National Heart, Lung, and Blood
Institute Scientific Statement have identified the metabolic syndrome as a group of
interrelated metabolic risk factors. The presence of these factors identifies a person at
risk for atherosclerotic cardiovascular disease and type 2 diabetes mellitus. Key risk
factors include abdominal obesity and insulin resistance. Additionally three of five o f the
following risk factors constitutes a diagnosis of metabolic syndrome: abdominal obesity
(waist circumference of >102 centimeters in men and >88 centimeters in women),
elevated fasting glucose of > 100 mg/dL, elevated triglycerides o f >150 mg/dL, low HDL
of <40 mg/dL in men and <50 mg/dL in women, and hypertension, defined as a systolic
pressure of >130 mm Hg and a diastolic pressure of >85 mm Hg. Metabolic syndrome is
associated with a variety o f conditions, including fatty liver .
The economic impact of chronic illnesses, specifically fatty liver disease and
obesity, is a burden to the health care system. While these diseases are often associated
together, they are also linked with a higher risk for several other serious health conditions
such as hypertension, type 2 diabetes, hypercholesterolemia, and coronary artery disease.
Direct medical costs and indirect costs such as absenteeism from work, decrease
productivity, and disabilities are increasing with the rise o f obesity and fatty liver disease.
Baumeister et al (2008) reported an increase of 26% in health care costs of a patient
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diagnosed with fatty liver disease. There were reports the cost of obesity in 2008 to be
estimated as high as $147 billion.
The current treatment of fatty liver disease remains diet, exercise and weight loss,
though there is little data to support the intensity. Maintaining weight loss in clinical
practice is difficult despite the benefits.
Aim:
The aim of this study was to describe the relationship of the intensity of care management
on education and support lifestyle changes to improve metabolic parameters in patients
with fatty liver disease.
Methodology
A repeated measures non experimental feasibility study design was used for this
study. The sample was recruited from patients referred to Southern California Liver
Centers with elevated liver enzymes. Between September 2011 and January 2012, 17 (13
adults and 4 adolescents) patients were identified with a diagnosis of fatty liver disease.
Inclusion criteria were elevated liver enzymes and the exclusion o f all other liver disease.
Patients were both English and Spanish speaking. The study procedures, including the
protocols for health care and obtaining informed consent were reviewed and approved by
the administrative and Univeristy institutional review boards.
Demographic Data:
Demographic data was obtained through the clinic directed questionnaire and
chart review.
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Medical History:
Co-morbidities were assessed through medical record audits, diagnostic (ICD9
codes), health care utilization (outpatient, inpatient, and emergency room encounters),
patient history. All medication and pharmacy information was taken at each visit as
standard procedure in the clinic. Patients were/are asked to bring in all medications to
verify dosage and frequency. At the initial visit personal and family history are taken
including diseases related to liver, diabetes, cancer, cardiovascular, and obesity and risk
factors for such diseases.
Clinical Criteria:
NAFLD was diagnosed based on a combination of clinical features, blood profile,
and radiological imaging or liver biopsy. The blood profile included evidence of elevated
liver enzymes, gamma-glutamyl transpeptidase, and alkaline phosphate. Radiological
features identified fatty infiltrations or fibrosis. A liver biopsy identified the percent of
steatosis or provided a NAFLD Activity Score (NAS).
Nutritional Assessment:
Nutritional assessment was based on the following: anthropometry, 24 hour diet
recall, and laboratory values of vitamins and minerals. All measurements were taken by
the same investigator to avoid any inter-observer variation.
Anthropometry:
All patients had a baseline body mass index (BMI) calculated at each clinic visit.
BMI was calculated by dividing weight in kilograms by height in meters squared and
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calculated according to the Centers for Disease Control and Prevention adults charts.
BMI was used as a baseline comparison. The waist circumference was taken at the level
of the iliac crest, placing a tape measure in a horizontal plane (parallel to the floor) with
participant standing. The measurement was taken at the end of expiration and snug but
not compressing the skin. Additional anthropometric measurements include the
following midarm circumference (MAC), triceps skin fold thickness (TST), biceps skin
fold thickness (BST), and handgrip strength. MAC was measured midway between the
tip of the shoulder and the tip of the elbow (olecranon process and the acromium) to the
nearest millimeter with a measuring tape for both the right and left arm. The participants
palm was facing the thigh. TST and BST, established measures o f fat stores, was
measured to the nearest millimeter on both arms using the Harpenden skin fold calipers in
a standard manner. Each measurement was taken three times and the average values
calculated and recorded (Lee & Nieman, 2007).
Visceral proteins
Serum albumin concentration is the most frequently used laboratory measure of
nutritional status. It has been used to assess change in nutritional status and stratifying
the risk of malnutrition. Serum proteins are affected by capillary permeability, drugs,
impaired liver function, and inflammation. In a dehydrated patient, albumin levels may
be falsely high due to decrease plasma volume. Because of a relatively long half-life of
approximately 14-20 days, albumin has been identified as a marker of chronic nutritional
status. Albumin is expected to return to normal as the inflammatory response resolves.
Dietary intake and assessment

78
The assessment of the individual patient’s intake was determined by the dietary
recall method of the patient. The patient was instructed to write down the daily intake
and time of intake in a provided food diary. If they did not bring this diary, the provider
reviewed the previous 24 diet recall of the patient at the time of the visit. The objective
was to determine the categories o f food eaten based on the pyramid.
Lifestyle Changes
The changes in lifestyle were determined by self-reported modifications of diet
and exercise. The patient set goals at each visit and reviewed at subsequent visits with
the APRN. The goals set involved changes or modifications in diet, exercise, and sleep
patterns.
Statistical Analysis
All data was entered into Statistical Packages for the Social Sciences (SPSS) version 16.0
(Chicago, Illinois, USA) software for analysis. Descriptive statistics were calculated for
all analysis variables.
Results
Seventeen patients with diagnosed fatty liver disease were identified during
September 2011 through January 2012. There were 13 adults and 4 adolescents. The
mean age of the adults was 58.8 ±12.9 (range 29-72 years) and the mean age of the
adolescents was 16 years ±2.9 (range 12-17 years). The majority of patients (n=15)
chose to respond to the assessment interviews in English. All participants had a
diagnosis of elevated liver enzymes for referral to the specialist. Obesity was seen in 100
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% of the participants; not surprising given that obesity is a risk factor for NAFLD. The
initial laboratory values indicated a mild to moderate increase in liver injury tests. The
hepatic function was intact. There was no biochemical evidence o f cirrhosis. The
laboratory results indicated non cirrhotic liver patients, without infection or anemia. The
liver enzymes were elevated in all the adults and adolescents. The basic demographic
and clinical features are presented in Table 7.
Table 7: Basic Demographic and Clinical Features

D em ographic Data and Clinical Features
adults n=13, a d o lescen ts n=4 u n less o th e r w ise stated

m n mamm
WBC

6.4 ±1.4

6.911.4

3.8-10,8 th o u san d /u L

H6B

14.2511.4

13.710.73

11.7-15.5 g/dL

Pits

242.8159.6

277.75141.7

140-400 thou san d /u L

ALT

71.5±43.8

66.651396.6

6-40 U/L

AST

49.5+27.8

42..3114

10-35U/L

GGT

201.51262.2 n=6

30.5126.2 n=2

0-45 U/L fem ale
0-65 U/L m ale

Albumin

4.29+0.39

4.5+0.21

3.6-5.1 g/dL

INR

1.0310.9

1.051-0.07
n=2

9.0-11.5 sec

DM

5 /1 3

1 /4

HTN

4 /1 3

0 /4

CAD

0 /0

0 /0

Hyperlipidemia

6 /1 3

1 /4

:

Patients were followed every 2-3 months but tailored to the individual patient
needs and preferences. Each structured visits lasted 30-45 minutes to assess patient
clinical condition, discuss lifestyle changes and develop and evaluate goals. At the initial
visit, the laboratory tests include a CBC, CMP, lipid panel, fasting insulin, hemoglobin
A1C, vitamins E, B6, K, D, and folate, and minerals Calcium, phosphorus, zinc, copper,
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iron, selenium, and magnesium. At subsequent visits, laboratory values of CBC and
CMP, and other labs as directed by patient evaluation and calculated BMI were done.
Both the adult and adolescent groups had co-morbidities. There was almost 50%
of Diabetes type 2, hypertension, and hyperlipidemia seen in the adults. Surprisingly,
one adolescent patient was diagnosed as pre-diabetic and borderline hyperlipidemia. At
the time, he was not placed on medications. Diet and exercise were prescribed by his
primary physician for treatment.
Initial anthropometric measurement of waist, arm circumference, bicep and tricep
skin fold, and BMI were increased in both groups (Table 8). The waist measurement of
the adults was 41.5 inches ±2.68 and the adolescent waist was 43 inches ±6.14. The mid
arm circumference of the right side was 32.5 cm ± 1.64 for adults and 37.3 cm ± 1.43 for
adolescents. The left mid arm circumference was 34 cm ± 1.86 and 37 cm ±1 .53, adults
and adolescents respectively. The triceps was measured for both right and left in the
adults and adolescents. The results were 20.5 mm±3.83 and 21.4 mm±4.65 in adults and
29.5 mm±2.12 and 27.4 mm±6.22 in adolescents. The biceps in the adults and
adolescents were also measured on the right and left side. The adults biceps for the right
was 19.6mm ±5.68 and for the left was 20.17mm±4.54. The adolescent right and left
bicep was 28 mm±9.89 and 33.5 mm±9.19, respectively.
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Table 8: Initial Anthropometric Measurements

Waist

41.5 + 2.68

43 ± 6 .1 4

<35 inches

Mid arm
circumference, left
non dom inant

13.35 ± 1.86

14.66 ± 1 .5 3

>22

Triceps, left non
dom inant

21.4 ± 4.65

27.4 + 6,22

Range 13.8-14.2 males
based on age
Rang e 22.3-24.9
fem ales based on age

BMI

30.93 ± 3.7

33.33 ± 6 .3

18-25

Over the six months of assessment, the adults lost weight, decreasing their body
mass index (BMI) from 30.9 initially to 30.3 at six months. The adolescents increased
their BMI initially at 33.3 to 35 at six months. During this time period, the height of the
adolescent remained unchanged. At six months, 2 of the adolescents began to increase in
height (Table 9).
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Table 9: Body Mass Index changes over 6 months in Adults and Adolescents

30

■ A dults
□ A d o lescen ts

initial

3 m o n th s

6 m o n th s

Laboratory studies indicated both groups were non cirrhotic (Table 7). Albumin
levels were 4.29 ±0.39 and 4.5 ±0.21 in adults and adolescents respectively. The GGT
was initially high 20.1 ±206.2 (n=6) in the adults and 30.5 ±26.2 (n=2) in the adolescents
Initial elevated liver enzymes of ALT 71.5 ±43.8 and 66.65 ±39.6, and AST 49.5 ±27.8
and 42.3 ±14 in the adults and adolescents respectively were found (Table 10). At three
months, the ALT and AST were normal in the adolescents. While in the adults, the ALT
and AST were normal in 55% and 44% respectively.
At six months, the ALT and AST remained normal in the adolescents (Table 11). While
in the adults, the ALT and AST continued to decrease to normal levels.
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Table 10: Initial Liver Function Tests and BMI of Adults and Adolescents

80 ,

60 -j

■ ad u lts

40 4

I
30 J

(

20 j
i

10 -j

Table 11: Liver Function Tests at 6 Months in Adults and Adolescents

■ Adults
□ A dolescents

AST

ALT
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A healthier choice of foods over the six month period emerged. For the adults,
diet changes were more difficult since 85% of the adults skipped either breakfast or
lunch. There were two adults who skipped both breakfast and lunch. Initially both
groups did not meet the required number of servings. The adults did consume the better
diet, through poor, and the adolescents consumed higher fat content. At six months,
though not adequate, improvement was noted in the food choices made (Table 11). The
participants increased fruits and vegetables to an average of 6 servings in the adults and 2
3A servings in the adolescents. Adults increased their servings o f protein, and grains,
while decreasing their fat intake at six months. Adolescents reported an increased
awareness of better food choices through the school lunch program. They found ways to
improve their school lunch program by removing breading off the chicken tenders and
adding more vegetables to the salad, a choice they had rarely done before.
Table 12; Diet analysis at onset and 6 months

8

7 -I

■ Adults
3 Adults 6 mos
3 Adolescents
Adolescents 6 mos
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Exercise was addressed at each visit. The adults found exercise to be difficult to schedule
in their daily activities. However, they did increase their exercise times to twice a week
for an average of 30 minutes. They stated it was hard to incorporate exercise into their
lives as they usually exercised by themselves. The adolescents increased their physical
exercise to 5 times a week lasting 1 to 1.5 hours per session. The family became part of
the exercise team.
Discussion
The current study was designed to address the intensity of care management as
evidenced by length of scheduled visits, time spent developing new goals and reviewing
previous identified goals, needed on education and supporting of lifestyle changes to
improve metabolic parameters in patients with fatty liver disease. In this study, the
protocol was for visits every three months, The adults self-selected for monthly visits for
weight checks and provider visits every 2-3 months. The adolescents chose to continue
with every 3 month visits citing family constraints. We did not add medication to either
group.
Each visit was/is a re-evaluation o f where the participant has been and where they
are headed in their changes of lifestyle. Goals are evaluated, modified, and created with
the participant. Listening to your patient, becoming an advocate and cheerleader for their
successes and celebrating the successes-small or big, help the patient. The goal is a
healthy lifestyle-it takes work and commitment.
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Though most clinical trials have used a balanced diet with restriction, we focused
on the food pyramid and healthy choices of complex carbohydrates and a decrease of fats
in the diet. Adults increased their servings of fruits and vegetables, proteins, and grains.
Though the adolescents presented with a higher BMI, the adults presented with higher
ALT and AST.
A major finding in this study was that frequency and time allocated of visits and
mutual goal setting improved the outcome of the liver enzymes. Outside of clinical trials,
management of fatty liver is feasible, but intense. Improvement occurs with dedicated
time and a contract with the patient, listening to the patient, allows for tailoring the
program albeit, chemical and metabolic improvement is slows, it does occur.
Modifications of diet and increased exercise were aimed to promote weight loss.
Lifestyle changes were initiated and discussed. Adolescents require full participation and
family support in lifestyle changes o f the patient to achieve the goals of therapy. One
adolescent stated it gave her time with her mother to talk on their daily walks.
Though our results our similar to the literature suggesting a lifestyle change is
needed to manage fatty liver disease, this study of a small sample size, provide additional
data supporting the need for intensive dedicated time to the patient. It supports the need
for the patient to be part of the structuring of their lifestyle changes. Education and
listening to the patient becomes a key component to each visit. The guidelines for dietary
intake were taken from myplate.com. Though simple, it was user friendly for this
population.
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Conclusion:
Fatty Liver Disease is a difficult disease to treat. The United States culture
provides an environment of high-calorie food, “super-sized” portions, and busy daily
routines that seem to preclude time for exercise. As the risk of this chronic liver disease
becomes more common, insulin resistance, type II diabetes, and cardiovascular disease
increases. Though pharmacologic intervention continues to be explored, there remains
no consensus for the use of any single drug or combination of drugs for the treatment of
fatty liver disease.
Uneo, Sugawara and Sujaku (1997) found a three month restrictive diet and
exercise program led to a decrease in liver enzymes, improved cholesterol and blood
glucose levels in patients with NAFLD. St. George et al. (2009) reported increased
physical activity reduced aminotransferase levels and weight loss in a three month study.
The literature describes a 5-8% weight loss is needed to improve liver function
tests. Yet, in this small study, the adolescents did not demonstrate weight loss, yet
improved liver function tests at three months. Not every patient with fatty liver disease
requires aggressive therapy, but every patient should be started on a healthy diet and
regular exercise program. Practical considerations for follow up is scheduling a longer
clinic visit and listening to your patients. It is labor intensive, it could be cost effective
for the patient, and the APRN can run this clinic.
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A Descriptive Study of Nutritional Parameters in End-Stage Liver Disease
Abstract:
Nutrition is one of the most important factors which can influence overall
mortality and morbidity. It is well documented, liver cirrhosis, end-stage liver disease
(ESLD), drives a patient to a catabolic state thus depleting them o f essential nutrients.
With the standard parameters o f nutritional assessment often invalid in ESLD, it becomes
difficult to identify and assess nutritional status. Simple and easy methods are needed to
identify the patients approaching the state of malnutrition.
The purpose of this study was to (1) identify the incidence of malnutrition in
patients with compensated liver disease utilizing defined nutritional parameters
(anthropometric measurements, hand grip strength, and laboratory values) and (2)
examine the degree of malnutrition patients with end stage liver disease secondary to
viral hepatitis, metabolic (non alcoholic steatohepatitis) and alcoholic liver disease.
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The results of this study provide a description of nutritional parameters of
cirrhosis based on the etiologies of Hepatitis C virus (n=15), Non-Alcoholic
Steatohepatitis (n=9), and Alcoholic Liver Disease (n=9). Thirty three (33) subjects were
included in this retrospective study. The disease severity was Child A-14 and Child B11. Diabetes type II and hypertension were the most common comorbitities. The BMI
average across the groups was 31. Clinical assessment shows a trend toward increase in
malnutrition. Identification of the earlier stages of malnutrition is challenging, it develops
insidiously and maybe masked by edema, however this information is critical for
intervention to prevent further complications in the progression o f liver disease.
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Introduction:
The liver plays a fundamental role in our body and influences the nutritional
status. When a liver injury occurs, malnutrition may be exacerbated. Malnutrition has
been reported as high as 90% depending on the patient population studied and the disease
severity (Italian Multicentre Cooperative Project, 1994). Protein energy malnutrition is a
frequent finding in patients with liver cirrhosis, and malnutrition represents a risk factor
influencing both short term and long term survival (Campillo, Richardet, Scherman, &
Bories, 2003; Matos, Porayko, Fransisco-Ziller, & DiCecco, 2002; & Roongisuthipong,
Sobbonliduk, Nantiny, & Songchitsomboon, 2001). In the cirrhotic patient, lean patients
with a Body Mass Index (BMI) of less than 18 .5 kg/m2 has been associated with protein
energy malnutrition (PEM), though obese patients with a greater than 25 kg/m2 has a
higher prevalence and increases the risk for hepatocellular cancer (Callee, Rodriguez,
Walker-Thurmond, & Thun, 2003; Inoue, Iwasaki, Otani, Sasazuki, Noda, Tsugane,.
2006; Muto, Watanabe, Moriwaki, Suzuki, Kato, Kato, M., Nakamura, Higuchi,
Nishiguchi, Kumada, Ohashi, 2006; Yoshiji, Noguchi, Kitade, Ikenaka, Namisaki,
Yoshii, Yanase, Yamazaki, Tsujimoto, Akahane, Kawaratani, Uemura, & Fukui, 2009).
Due to the multiple causes of cirrhosis, there are a variety o f dietary habits from
PEM to over nourishment. However, most of these studies regarding nutritional intake
have focused on hospitalized patients ( Muto et al, 2006; Albertino, Gatta, Amodio,
Merkel, DiPascoli, Boffo, & Caregaro, 2001; Italian Multi center Cooperative Project on
Nutrition in Liver Cirrhosis, 1994). Though not fully understood, there are multifactorial
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mechanisms contributing to malnutrition in cirrhosis: poor dietary intake, malabsorption,
increased protein losses in the intestine, low protein synthesis, hypermetabolism, and
disturbances in substrate utilization. (The diet often recommended is low sodium to
control the peripheral edema and ascites. Food may become unpalatable leading to
decrease in intake. A low zinc or magnesium level can distort or decrease taste sensation
(Madden, Bradbury, & Morgan, 1997; &Yang, Lai, Chiang, Chen, & Chen, 2004).
Poor nutritional status is the single reversible prognostic marker in cirrhosis.
Multiple studies have suggested a causal relationship between malnutrition and survival
(Alberino et al, 2001; Norman, Kirchner, Lochs, & Pirlich, 2006). Notably, malnutrition
has been associated with impaired immunity and increased susceptibility to infections.
There is currently is no gold standard for clinical assessment. Body weight is
influenced by ascites and peripheral edema in the patient with liver disease, though it was
validated in one study (Campillo Richardet, & Boris, 2006). Nitrogen balance has been
associated with improved outcome during critical illness, but rarely measured outside
clinical trials (McGhee, Henderson, & Millikan, 1983). Plasma protein and
anthropometry are common bedside assessments but have significant drawbacks.
The purpose of this study was to identify the incidence o f malnutrition in patients
with compensated liver disease utilizing defined nutritional parameters (anthropometric
measurements, hand grip strength, and laboratory values) and examine the degree of
malnutrition patients with end stage liver disease secondary to viral hepatitis, metabolic
(NASH) and alcoholic liver disease.
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Methods:
A retrospective study was conducted to identify malnutrition in outpatients with
liver cirrhosis and to compare the differences in the nutritional status o f the patients with
NASH, HCV, alcohol, and combinations of diseases using a variety o f objective
measures including clinical examinations, anthropometric measurements and dietary
intake. One hundred five charts were reviewed and the sample included thirty three
subjects meeting the criteria of diagnosis cirrhosis, nutritional data available and not
currently in a clinical trial. Secondary data analysis was conducted on data abstracted
from the medical record of patients receiving services from Southern California Liver and
GI Centers in San Diego and Orange Counties. The Institutional Review Board of the
University of San Diego approved the study protocol and Southern California Liver and
GI Center agreed to allow the review of patient’s chart. The data collected was routine
clinical procedure for the clinic.
Nutritional Assessment
The nutritional assessment was conducted through 24 hour patient recall. For
each patient the following data were included: anthropometric measurements, evaluation
of diet through food on my plate, and laboratory tests.
Anthropometric measurements
Each patient was weighed on a balance beam scale. Height was taken standing in
bare feet with a stadiometer. Body mass index was computed as body weight (kg)/height
(m2). Mid-arm circumference was measured at the midpoint between the tip of the
acromion and the olecranon process using a flexible tape measure. The arm was relaxed

with the palm of the hand facing forward. The vertical pinch was parallel to the long axis
of the arm. Skin fold measurements were determined at tricpes and biceps areas (mm),
according to standardized protocol. All the measurements were taken using Harpender
skin fold calipers with a pressure of 10g/mm3 applied to the surface area. The same
operator completed the readings to reduce measurement errors. Triceps skin fold
thickness and mid arm circumference can be measured and is used in patients with
advanced liver disease. These anthropometric measurements are only mildly affected by
fluid retention (Matos, Porayko,Francisco-Ziller, & Di Cecco, 2002). Muscle strength
was measured using a dyanometer. This is a hand held device designed to measure
muscle strength in a simple way. The participant was in a standing position with arms at
sides without touching their body. The elbow was slightly bent. The test was
administered on the non dominant hand. The participant squeezed the dynamometer with
as much force as possible, being careful to squeeze it only once. This was done 3 times
with a pause of 10-20 seconds between to avoid the affects o f muscle fatigue. The results
were recorded to the nearest pound or kilogram.
Dietary Intake
Twenty-four hour recall was evaluated through dietary interviews with the
patient.
Laboratory values
Laboratory values were measured by established laboratory methods. The
laboratory examination included alanine aminotransferase (ALT), aspartae
aminotransferase(AST), gamma-glutamyl transferase (GGT), alkaline phosphatase, total
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bilirubin, total, HDL and LDL cholesterol, triglyceride, hemoglobin, hematocrit, glucose,
insulin, serum ferritin, thyroid stimulating hormone (TSH), Prothrombin time (PTT), PT,
ENR, platelets, magnesium, uric acid, hgbAlC, vitamin d, vitamin a, and vitamin e.
Severity of Cirrhosis
Both the Child-Pugh (Child & Turcotte, 1964) and the MELD (Kamath, Wiesner,
Malinchoc, 2001) scores were used to classify the severity of cirrhosis. The Child-Pugh
score and he MELD score was derived from laboratory parameters.
Analysis:
Descriptive statistics were calculated for all analysis variables. Chi-square tests
for categorical variables and one-way anova for continuous variables were used to
examine bivariate relationships. Comparisons of measured values among the Child-Pugh
classifications-Grade A, B, And C and etiology o f cirrhosis were performed using one
way anova, SchifFe Post hoc..
Results:
The sample was comprised of 33 patients with diagnosed cirrhosis of the liver (17
men, mean age 56.4±9.4 and 19 woman, mean age 56.8±12.2) undergoing follow up
between June 2012 to March 2013. Liver cirrhosis was diagnosed by clinical and
laboratory profiles. All the subjects had liver biopsies or ultrasounds to confirm
cirrhosis. The etiology of cirrhosis was Hepatitis C virus (n-15), non-alcoholic steato
hepatitis (NASH) (n=9), alcohol (n=9), and a combination o f liver diseases (n=3). The
disease severity was categorized by Child-Pugh classification revealing Score A in 14

cases and Score B in 11 cases. The subjects have an average of 2.7 co-morbidities
ranging from 0-4. The most frequently seen co-morbidities were diabetes mellitus and a
history of hypertension. Ten percent of the subjects were taking 1-3 kinds of prescribed
medication and 90% were taking 4 or more medications. The demographic data and
clinical profile of the patients is presented in Table 13 and 14.
Table 13: Demographic Data of Participants.
N=
Age
Sex
Weightmean
190.79±46.2
Exercise
routine
yes/no
Co
morbidity
0/l-3/>4
Alcohol
drinking no, current
drinking,
past drinker
No of
prescribed
meds 0/13/>4

Hepatitis C NASH
Alcohol
15
9
9
56.4±13.9 44±11.1
58.1±9.4
Female-7
Female-8
Female-2
Male-2
Male-7
Male-7
188.6±45.8 195.7±43.3 189.4±56.9

HCV/NASH Alcohol/HCV
2
1
54±1.4
56
Female-2
Female-0
Male-0
Male-1

5yes

6 yes

0

<3-13
>3-2

<3-3
>3-9

<3-7
>3-2

<3-2

<3-0
>3-1

0

0

2-current
7past

0

0
1 past

8.3±2.4

5±2.8

8.8±2.3

10

0
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Table 14: Clinical Profile of Participants
Normal
values
ChildPugh A
Child
PughB
Child
Pugh C
MELD
Total
Bilirubin
INR
Albumin
HGB

Creatinine

Sodium
Potassium

0.2-1.2
mg/dL
0.9-1.1
sec
3.6-5.12
g/dL
11.715.5
g/dL
0.151.05
mg/dL
135-146
mmol/L
3.5-5.3
mmol/L

HCV/NASH Alcohol/HCV

Hepatitis
C
4

NASH

Alcohol

6

4

7

2

2

9.3±3.4
,95±.69

9.5±3.2
,96±.94

9±2.3
1.16±.87

12±4.24
1.1±1.06

9.4
1.8

1.9±2.7

1.2±.33

1.2±. 12

1.15±.21

1.3

3.7±.63

4.01±.56

3.48±.52

3.95±.35

3.1

13.01±2.5

12.6±1.14

12.3±1.8

12.9±1.2

14.3

1.27±.52

,79±.31

,75±.2

,75±.21

.83

137.4±3.7

139.7±1.8

134±3.5

138.5±3.5

139

4.1±.72

4.1±,26

3.9±.48

3.9±. 14

3.7

The nutritional parameters were identified by triceps skin fold thickness and hand
grip of the non-dominant hand, waist circumference, albumin, total protein, and my plate
categories of fruits, vegetables, protein, dairy, and empty calories, identified the subjects
with HCV with a higher waist circumference (43.0 inches±8.5) than the subjects with
NASH (35.17 inches±23.85) and subjects with alcohol as etiology of cirrhosis
(32.01±19.91). Tricep skin fold thickness, was decreased in all etiologies as was hand

grip strength, five to 10 percent in the participants with each etiology. The subjects with
NASH cirrhosis consumed more fruits, average 1.33 than either the HCV subjects or
alcohol subjects, 0.77 and 0.5 respectively. Vegetables and Protein, albeit low, was
consistent across groups ranging from 1.3 to 1.75 and 1.75 to 2.2 respectively.
Differences were shown in dairy with the HCV subjects consuming at least one dairy
product a day and the alcohol subjects consuming less than a quarter of a dairy product
daily. Interesting tp note, two of the subjects with alcohol cirrhosis continue to drink
actively. Alcohol intake was not noted in any of the other subjects or groups (see table
15and 16for details).
Table 15: Nutrition Intake of Patients According to Etiology.
Fruits
vegetables
protein
Dairy
Empty calories

Normal values
1 Vz -2 cups
daily
2-3 cups daily
46-56 grams
daily
3 cups daily
120-260
calories
depending on
gender daily

HCV
.77±.83

NASH
1.33±1.03

Alcohol
,5±1.0

1.6±1.0
2.2±1.39

1.3±1.0
2.0±.63

1.75±.957
1.75±.5

1.0±1.41
1.9±1.67

,66±.81
3.0±2.5

,25±.5
3.3±1.5
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Table 16: Nutritional Profile According to Etiology

Tricep Skin foldnon dominant

Hand grip-non
dominant

Waist
Circumference
Albumin
Total Protein

NASH

Alcohol

22.9±1.07

19.6±1.4

27.07±48

9.66±10,59

35.17±23.85

32.01±19.91

3.7±.64

4.01±.56

3.48±.52

7.2±.86

6.9±.37

6.87±.46

Normal
HCV
values
Range 13.8- 17.8cm±1.58
14.2 males
based on
age
Range 22.324.9
females
based on
age
Range 30.2- 14.6±9.8
57.7 males
based on
age
Range 17.235.3
females
based on
age
43.0±8.5
<35 inches
3.6-5.1
g/dL
6.2-8.3
g/dL

A one way anova between groups of analysis of variance was conducted to
explore the impact of Child Pugh scores on selected laboratory parameters-albumin, total
bili, alanine transfemase, prothrombin time, and anthropometric measurements of body
mass index and etiology. As expected, significance at 0.3, 0.32, and 0.001, respectively,
the higher the body mass index, the lower the albumin and the higher the total bili, the
higher the Child Pugh score, indicating the subject was worsening. Once cirrhotic,
etiology made no difference (see table 17).
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Table 17: Comparisons of Selected Measures with Child-Pugh Classifications

Body mass
index
Etiology
(NASH/HCV/
Alcohol/Others
Albumin
Total Bilirubin
ALT
Prothrombin
time

Normal
values
18-25

3.6-5.1 g/dL
0.2-1.2
mg/dL
6-40 U/L
9.0-11.5 sec

f

P

4.118

0.03

.556

.581

3.985
8.864

.031
0.001

1.232
.540

.309
.590

A one-way anova between groups analysis of variance was conducted to explore
the impact of disease etiology on nutritional intake, as measured by a 24 hour nutritional
recall and laboratory values of albumin, INR, and total protein. Subjects were divided
into 3 groups according to the etiology of cirrhosis- Group 1-HCV, Group 2-NASH, and
Group 3-alcoholic cirrhosis. There was no statistical significance (see table 18).
Table 18: Comparisons of selected nutritional parameters with Etiology of HCV, NASH,
and Alcohol
Albumin
INR
Grains
Veg
Fruits
Oils
Protein
Dairy
Empty calories
Skips breakfast
Skips lunch
Skips dinner

Normal Values
3.6-5.1 g/dL
0.9-1.1 sec
5-10 servings daily
2-3 cups daily
1 Vi-2 cups daily
15 percent of
calories consumed
46-56 grams daily
3 cups daily
120-260depending
on gender
0
0
0

F
1.251
.354
2.086
.362
1.022
8.533

P
.312
.787
.145
.782
.409
.001

.494
.556
.784

.692
.653
.479

6.870
2.831
.241

.003
0.071
.867
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Discussion:
Identifying the earlier stages of malnutrition is challenging. It develops
insidiously and maybe masked by edema. The earlier the diagnosis of malnutrition, the
earlier interventions can be started. It has been well documented complications of liver
disease increases with malnutrition (Cabre &Gassull, 1998). The nutritional status of
patients with liver cirrhosis has shown great diversity and there is no gold standard for
early diagnosis. Some have identified protein energy malnutrition and others have
excessive nutrition and obesity. Evaluating the nutrition from the perspective of
management of the underlying cause of cirrhosis may prevent additional liver injury. This
study categorized subjects with cirrhosis according to the top three disease entities of
cirrhosis. Laboratory evaluations, anthropometric measurements, 24 hour diet recall,
etiology of cirrhosis, ascites, edema, anasarca and Child Pugh score was completed on 33
patients.
Anthropometric measurements and handgrip strength have correlated well with
the dual-energy x-ray absorptiometry (DEXA) (Alvares-da-Silva, & Reverbel, 2005;
Figueriredi, Dickson, & Pasha, 2000; & Flore, Merli, & Andreoli, 1999). NASH
subjects had a higher handgrip strength than either the HCV or alcohol subjects. Alvaresda-Silva and colleagues (2005) found handgrip strength as an easy and effective tool in
assessing nutritional risk in patients with end stage liver disease. When taken serially, it
may become very useful in clinical practice. In this study the tricep skin fold thickness
and the hand grip strength of the non-dominant hand was decreased in all etiologies
indicating decrease muscle tone and strength. Serially measurements need to be taken to
validate the findings. One is cautioned the overuse of handgrip strength may
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overestimate the prevalence of malnutrition. The BMI was found to be higher in the
subjects with HCV, but all three groups averaged BMI of 31.13±8.57. As expected, the
NASH subjects had the highest BMI at 33.91±6.1 and the lowest BMI was the subjects of
alcoholic cirrhosis with a BMI of 29.1±7.1. Ascites and peripheral edema was minimally
reported in this population o f subjects.
Early identified poor diets may offer opportunities for nutritional counseling. In
this study, the subjects were not taking adequate nutrients. Consistently the subjects who
consumed fewer fruits, vegetables, protein, and dairy had an increase in empty calories.
Meals were skipped-breakfast the most common meal skipped. Previous research has
shown in healthy adults; breakfast is the most important meal of the day, setting the tone
for activity, wellness, and energy.
Muscle wasting and easy fatigability is well recognized in cirrhosis. Exercise is
relevant as the impact of physical fitness can be improved. However, in this study, the
subjects overall did very little exercise, citing fatigue and lack of energy as the source of
limited exercise. Discussion of exercise was documented in the patient’s record and
encouragement of walking was encouraged.
Clinical Assessment demonstrates a trend towards more malnourishment with
increasing clinical severity. A larger study sample is required to support these findings.
The goals of nutrition are to replenish malnourished individuals, maintain adequate
muscle and energy reserve, and manage patient’s symptoms to maximize quality o f life.
With the standard parameter of nutritional assessment often invalid in end-stage liver
disease, it becomes difficult to identify and assess nutritional status.

The results of this study must be interpreted in the context of limitations including
a cross sectional design, a small sample, and nutritional parameters documented in the
clinical chart. This data could form a baseline for future prospective studies and change
the practicing standards of operating practice in clinical practice. As there is no
longitudinal data available, continued analysis of nutritional parameters is warranted on
an outpatient status of persons with end-stage liver disease.

Conclusions:
Cirrhosis is considered a risk for malnutrition, but needs to be looked through the
lenses of etiology. Obesity may change the revision o f nutritional standards (Shiraki,
Nishiguchi, Saito, Fukuzama, Mizieta, Kaibori, Hanai, Nishimura, Shimizu, Tsurumi, &
Moriwaki, 2003). Nutritional support may improve clinical outcomes in those with early
cirrhosis. Preventing further nutrient and muscle depletion, correcting vitamin and
mineral deficiencies may minimize the risk of infection, debility, and deconditioning
(Campos, Matias, Coelho, 2003). Additional studies are needed to provide information
and nutritional therapies for patients with liver cirrhosis. Nutritional education is
important and recommended for patients with liver cirrhosis to help them in the balance
and selection o f foods with protein and nutrients.
This study continues to collect data identifying the nutritional parameters of the
patient with cirrhosis of the liver. This data is part of a longitudinal study looking at the
parameters of nutrition in the patient with end stage liver disease.
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PROPOSED PLAN OF RESEARCH
My dissertation has only touched the surface of my projected research plan. There are many
threads to pursue.
1.

What is the relationship between hospital visits, ED visits, physician visits, quality of life
and outcome of the patient with fatty liver disease and end stage liver disease.

2. What is the impact of disease state on the lifestyle changes over time?
3. How do we improve strategies to assess the liver patient? What is the dry weight versus
the wet weight (having edema and ascites)?
4.

Is a change in chemical injury tests and/or BMI a predictor of liver disease regression or
progression?

5. What are the characteristics of malnutrition with respect to etiology of cirrhosis?
This process of learning about research, a novice understanding of research and statistics, has
only increased my thirst of finding questions. The patients are the winners in this thirst for
knowledge. It is their experiences, their laboratory values, their anthropometric measurements,
which when collected and analyzed will help shape the knowledge known and only lad to more
questions.

